64 results on '"Rita E. Weathers"'
Search Results
2. Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study
- Author
-
Gregory T. Armstrong, Constance A. Owens, Rita E. Weathers, Aashish C. Gupta, James E. Bates, Stephen F Kry, Louis S. Constine, Qi Liu, Yutaka Yasui, Susan A. Smith, Bradford S. Hoppe, Rebecca M. Howell, Daniel A. Mulrooney, Ying Qiao, Wendy M. Leisenring, Eric J. Chow, Laurence E. Court, Suman Shrestha, Kevin C. Oeffinger, and Chelsea C. Pinnix
- Subjects
medicine.medical_specialty ,Heart Diseases ,medicine.medical_treatment ,Childhood Cancer Survivor Study ,Disease ,Coronary artery disease ,Cancer Survivors ,Neoplasms ,Internal medicine ,medicine ,Humans ,Dosimetry ,Radiology, Nuclear Medicine and imaging ,Survivors ,Child ,Radiometry ,business.industry ,Common Terminology Criteria for Adverse Events ,Hematology ,medicine.disease ,Radiation therapy ,Oncology ,Heart failure ,Cohort ,Cardiology ,business - Abstract
BACKGROUND AND PURPOSE We previously evaluated late cardiac disease in long-term survivors in the Childhood Cancer Survivor Study (CCSS) based on heart radiation therapy (RT) doses estimated from an age-scaled phantom with a simple atlas-based heart model (HAtlas). We enhanced our phantom with a high-resolution CT-based anatomically realistic and validated age-scalable cardiac model (HHybrid). We aimed to evaluate how this update would impact our prior estimates of RT-related late cardiac disease risk in the CCSS cohort. METHODS We evaluated 24,214 survivors from the CCSS diagnosed from 1970 to 1999. RT fields were reconstructed on an age-scaled phantom with HHybrid and mean heart dose (Dm), percent volume receiving ≥ 20 Gy (V20) and ≥ 5 Gy with V20 = 0 ( [Formula: see text] ) were calculated. We reevaluated cumulative incidences and adjusted relative rates of grade 3-5 Common Terminology Criteria for Adverse Events outcomes for any cardiac disease, coronary artery disease (CAD), and heart failure (HF) in association with Dm, V20, and [Formula: see text] (as categorical variables). Dose-response relationships were evaluated using piecewise-exponential models, adjusting for attained age, sex, cancer diagnosis age, race/ethnicity, time-dependent smoking history, diagnosis year, and chemotherapy exposure and doses. For relative rates, Dm was also considered as a continuous variable. RESULTS Consistent with previous findings with HAtlas, reevaluation using HHybrid dosimetry found that, Dm ≥ 10 Gy, V20 ≥ 0.1%, and [Formula: see text] ≥ 50% were all associated with increased cumulative incidences and relative rates for any cardiac disease, CAD, and HF. While updated risk estimates were consistent with previous estimates overall without statistically significant changes, there were some important and significant (P
- Published
- 2021
3. Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer
- Author
-
Lisa L. Hunter, Gordon P. Watt, Cecilia A. O'Brien, Rebecca M. Howell, John D. Boice, Laura Cervino, Meghan Woods, Marilyn Stovall, Eric J. Chow, Kathleen E. Malone, Judy Goldstein, Michele M. West, Xiaolin Liang, Lene Mellemkjӕr, Lawrence T. Dauer, Charles F. Lynch, Lauren E. Carlson, Emily S. Tonorezos, Roy E. Shore, Leslie Bernstein, Mark E. Robson, Rikke Langballe, Anne S. Reiner, Marinela Capanu, Anthony F. Yu, Jonine L. Bernstein, Irene Orlow, Susan A. Smith, Jennifer D. Brooks, Jørgen H. Olsen, Kristina M. Blackmore, Esther M. John, Rita E. Weathers, Irene Harris, Julia A. Knight, and Elaine Ramos
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,BMI, body mass index ,CAD, coronary artery disease ,CAD - Coronary artery disease ,Coronary artery disease ,Breast cancer ,prevention ,Internal medicine ,Epidemiology ,Mini-Focus Issue: Radiation and Cardiovascular Disease ,Medicine ,Risk factor ,skin and connective tissue diseases ,Original Research ,Ischemic disease ,treatment ,business.industry ,RT, radiation therapy ,medicine.disease ,Radiation therapy ,Oncology ,risk factor ,women’s oncology ,Cardiology ,epidemiology ,ischemic disease ,Cardiology and Cardiovascular Medicine ,business ,BMI - Body mass index - Abstract
Background Radiation therapy (RT) for breast cancer increases risk of coronary artery disease (CAD). Women treated for left- vs right-sided breast cancer receive greater heart radiation exposure, which may further increase this risk. The risk of radiation-associated CAD specifically among younger breast cancer survivors is not well defined. Objectives The purpose of this study was to report CAD risk among participants in the Women’s Environmental Cancer and Radiation Epidemiology Study. Methods A total of 1,583 women who were, Central Illustration
- Published
- 2021
4. Subsequent Neoplasm Risk Associated With Rare Variants in DNA Damage Response and Clinical Radiation Sensitivity Syndrome Genes in the Childhood Cancer Survivor Study
- Author
-
Bin Zhu, Kristine Jones, Eric Karlins, Gregory T. Armstrong, Stephen W. Hartley, Belynda Hicks, Byron S. Sigel, Jeremy A. Miller, Stephen J. Chanock, Rita E. Weathers, Joshua N. Sampson, Yutaka Yasui, Smita Bhatia, Lucie M. Turcotte, Leslie L. Robison, Diana M. Merino, Margaret A. Tucker, Lindsay M. Morton, Megan N. Frone, Michael Arnold, Wendy M. Leisenring, Casey L. Dagnall, Joseph P. Neglia, Meredith Yeager, Danielle M. Karyadi, Susan A. Smith, Amy Berrington de Gonzalez, and Rebecca M. Howell
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,DNA damage ,business.industry ,Childhood cancer ,Childhood Cancer Survivor Study ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Radiation sensitivity ,030220 oncology & carcinogenesis ,Internal medicine ,Original Reports ,Medicine ,Neoplasm ,business ,Gene - Abstract
PURPOSE Radiotherapy for childhood cancer is associated with elevated subsequent neoplasm (SN) risk, but the contribution of rare variants in DNA damage response and radiation sensitivity genes to SN risk is unknown. PATIENTS AND METHODS We conducted whole-exome sequencing in a cohort of childhood cancer survivors originally diagnosed during 1970 to 1986 (mean follow-up, 32.7 years), with reconstruction of doses to body regions from radiotherapy records. We identified patients who developed SN types previously reported to be related to radiotherapy (RT-SNs; eg, basal cell carcinoma [BCC], breast cancer, meningioma, thyroid cancer, sarcoma) and matched controls (sex, childhood cancer type/diagnosis, age, SN location, radiation dose, survival). Conditional logistic regression assessed SN risk associated with potentially protein-damaging rare variants (SnpEff, ClinVar) in 476 DNA damage response or radiation sensitivity genes with exact permutation-based P values using a Bonferroni-corrected significance threshold of P < 8.06 × 10−5. RESULTS Among 5,105 childhood cancer survivors of European descent, 1,108 (21.7%) developed at least 1 RT-SN. Out-of-field RT-SN risk, excluding BCC, was associated with homologous recombination repair (HRR) gene variants (patient cases, 23.2%; controls, 10.8%; odds ratio [OR], 2.6; 95% CI, 1.7 to 3.9; P = 4.79 × 10−5), most notably but nonsignificantly for FANCM (patient cases, 4.0%; matched controls, 0.6%; P = 9.64 × 10−5). HRR variants were not associated with likely in/near-field RT-SNs, excluding BCC (patient cases, 12.7%; matched controls, 12.9%; P = .92). Irrespective of radiation dose, risk for RT-SNs was also associated with EXO1 variants (patient cases, 1.8%; controls, 0.4%; P = 3.31 × 10−5), another gene implicated in DNA double-strand break repair. CONCLUSION In this large-scale discovery study, we identified novel associations between RT-SN risk after childhood cancer and potentially protein-damaging rare variants in genes involved in DNA double-strand break repair, particularly HRR. With replication, these results could affect screening recommendations for childhood cancer survivors and risk-benefit assessments of treatment approaches.
- Published
- 2020
5. Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays.
- Author
-
Xiaohong R Yang, J Keith Killian, Sue Hammond, Laura S Burke, Hunter Bennett, Yonghong Wang, Sean R Davis, Louise C Strong, Joseph Neglia, Marilyn Stovall, Rita E Weathers, Leslie L Robison, Smita Bhatia, Kiyohiko Mabuchi, Peter D Inskip, and Paul Meltzer
- Subjects
Medicine ,Science - Abstract
Ionizing radiation is an established risk factor for breast cancer. Epidemiologic studies of radiation-exposed cohorts have been primarily descriptive; molecular events responsible for the development of radiation-associated breast cancer have not been elucidated. In this study, we used array comparative genomic hybridization (array-CGH) to characterize genome-wide copy number changes in breast tumors collected in the Childhood Cancer Survivor Study (CCSS). Array-CGH data were obtained from 32 cases who developed a second primary breast cancer following chest irradiation at early ages for the treatment of their first cancers, mostly Hodgkin lymphoma. The majority of these cases developed breast cancer before age 45 (91%, n = 29), had invasive ductal tumors (81%, n = 26), estrogen receptor (ER)-positive staining (68%, n = 19 out of 28), and high proliferation as indicated by high Ki-67 staining (77%, n = 17 out of 22). Genomic regions with low-copy number gains and losses and high-level amplifications were similar to what has been reported in sporadic breast tumors, however, the frequency of amplifications of the 17q12 region containing human epidermal growth factor receptor 2 (HER2) was much higher among CCSS cases (38%, n = 12). Our findings suggest that second primary breast cancers in CCSS were enriched for an "amplifier" genomic subgroup with highly proliferative breast tumors. Future investigation in a larger irradiated cohort will be needed to confirm our findings.
- Published
- 2015
- Full Text
- View/download PDF
6. Radiation Dose and Volume to the Pancreas and Subsequent Risk of Diabetes Mellitus: A Report from the Childhood Cancer Survivor Study
- Author
-
Charles A. Sklar, Kevin C. Oeffinger, Sogol Mostoufi-Moab, Lillian R. Meacham, Patrick Hilden, Chaya S. Moskowitz, Danielle Novetsky Friedman, Rita E. Weathers, Emily S. Tonorezos, Suzanne L. Wolden, Leslie L. Robison, John Whitton, Joanne F. Chou, Susan A. Smith, Wendy M. Leisenring, Rebecca M. Howell, Eric J. Chow, and Gregory T. Armstrong
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Diabetes risk ,Adolescent ,Childhood Cancer Survivor Study ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cancer Survivors ,Neoplasms ,Diabetes mellitus ,Internal medicine ,Diabetes Mellitus ,Humans ,Medicine ,Child ,Radiation Injuries ,Pancreas ,030304 developmental biology ,0303 health sciences ,business.industry ,Cancer ,Dose-Response Relationship, Radiation ,Radiotherapy Dosage ,Articles ,Middle Aged ,medicine.disease ,Confidence interval ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Relative risk ,North America ,Female ,business ,Body mass index - Abstract
Background Childhood cancer survivors exposed to abdominal radiation (abdRT) are at increased risk for diabetes mellitus, but the association between risk and radiation dose and volume is unclear. Methods Participants included 20 762 5-year survivors of childhood cancer (4568 exposed to abdRT) and 4853 siblings. For abdRT, we estimated maximum dose to abdomen; mean doses for whole pancreas, pancreatic head, body, tail; and percent pancreas volume receiving no less than 10, 20, and 30 Gy. Relative risks (RRs) were estimated with a Poisson model using generalized estimating equations, adjusted for attained age. All statistical tests were two-sided. Results Survivors exposed to abdRT (median age = 31.6 years, range = 10.2–58.3 years) were 2.92-fold more likely than siblings (95% confidence interval [CI] = 2.02 to 4.23) and 1.60-times more likely than survivors not exposed to abdRT (95%CI = 1.24 to 2.05) to develop diabetes. Among survivors treated with abdRT, greater attained age (RRper 10 years = 2.11, 95% CI = 1.70 to 2.62), higher body mass index (RRBMI 30+ = 5.00, 95% CI = 3.19 to 7.83 with referenceBMI 18.5–24.9), and increasing pancreatic tail dose were associated with increased diabetes risk in a multivariable model; an interaction was identified between younger age at cancer diagnosis and pancreatic tail dose with much higher diabetes risk associated with increasing pancreatic tail dose among those diagnosed at the youngest ages (P < .001). Radiation dose and volume to other regions of the pancreas were not statistically significantly associated with risk. Conclusions Among survivors treated with abdRT, diabetes risk was associated with higher pancreatic tail dose, especially at younger ages. Targeted interventions are needed to improve cardiometabolic health among those at highest risk.
- Published
- 2019
7. Role of radiotherapy and chemotherapy in the risk of leukemia after childhood cancer: An international pooled analysis
- Author
-
Cristina Veres, Rita E. Weathers, D.L. Winter, Ibrahima Diallo, Florent de Vathaire, Rebecca M. Howell, Margaret A. Tucker, Carole Rubino, Rodrigue S. Allodji, Mark P. Little, Michael M. Hawkins, Nadia Haddy, Marie-Cécile Le Deley, and Lindsay M. Morton
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Childhood cancer ,Article ,03 medical and health sciences ,0302 clinical medicine ,Cancer Survivors ,Internal medicine ,medicine ,Humans ,Child ,Chemotherapy ,business.industry ,Infant, Newborn ,Myeloid leukemia ,Infant ,Odds ratio ,medicine.disease ,Confidence interval ,Radiation therapy ,Leukemia ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Child, Preschool ,Bone marrow ,business - Abstract
Childhood cancer survivors are at increased risk for second primary leukemia (SPL), but there is little consensus on the magnitude of some risk factors because of the small size of previous studies. We performed a pooled analysis of all published studies with detailed treatment data, including estimated active bone marrow (ABM) dose received during radiation therapy and doses of specific chemotherapeutic agents for childhood cancer diagnosed from 1930 through 2000, in order to more thoroughly investigate treatment-related risks of SPL. A total of 147 SPL cases (of which 69% were acute myeloid leukemia [AML]) were individually matched to 522 controls, all from four case-control studies including patients from six countries (France, United Kingdom, United States, Canada, Italy and Netherlands). Odds ratios (OR) and corresponding 95% confidence intervals (CIs) were calculated using conditional logistic regression, and the excess OR per Gray (EOR/Gy) was also calculated. After accounting for the other therapies received, topoisomerase II inhibitor was associated with an increased SPL risk (highest tertile vs none: OR = 10.0, 95% CI: 3.7-27.3). Radiation dose to the ABM was also associated with increased SPL risk among those not receiving chemotherapy (EOR/Gy = 1.6, 95% CI: 0.1-14.3), but not among those who received chemotherapy (CT). SPL were most likely to occur in the first decade following cancer treatment. Results were similar when analyses were restricted to AML. The evidence of interaction between radiation and CT has implications for leukemogenic mechanism. The results for topoisomerase II inhibitors are particularly important given their increasing use to treat childhood cancer.
- Published
- 2020
8. Body region-specific 3D age-scaling functions for scaling whole-body computed tomography anatomy for pediatric late effects studies
- Author
-
Aashish C Gupta, Constance A Owens, Suman Shrestha, Choonsik Lee, Susan A Smith, Rita E Weathers, Tucker Netherton, Peter A Balter, Stephen F Kry, David S Followill, Keith T Griffin, James P Long, Gregory T Armstrong, and Rebecca M Howell
- Subjects
Adult ,Male ,Photons ,Adolescent ,Phantoms, Imaging ,Infant, Newborn ,Infant ,Article ,Child, Preschool ,Humans ,Female ,Child ,Radiometry ,Tomography, X-Ray Computed ,General Nursing ,Retrospective Studies - Abstract
Purpose. Radiation epidemiology studies of childhood cancer survivors treated in the pre-computed tomography (CT) era reconstruct the patients’ treatment fields on computational phantoms. For such studies, the phantoms are commonly scaled to age at the time of radiotherapy treatment because age is the generally available anthropometric parameter. Several reference size phantoms are used in such studies, but reference size phantoms are only available at discrete ages (e.g.: newborn, 1, 5, 10, 15, and Adult). When such phantoms are used for RT dose reconstructions, the nearest discrete-aged phantom is selected to represent a survivor of a specific age. In this work, we (1) conducted a feasibility study to scale reference size phantoms at discrete ages to various other ages, and (2) evaluated the dosimetric impact of using exact age-scaled phantoms as opposed to nearest age-matched phantoms at discrete ages. Methods. We have adopted the University of Florida/National Cancer Institute (UF/NCI) computational phantom library for our studies. For the feasibility study, eight male and female reference size UF/NCI phantoms (5, 10, 15, and 35 years) were downscaled to fourteen different ages which included next nearest available lower discrete ages (1, 5, 10 and 15 years) and the median ages at the time of RT for Wilms’ tumor (3.9 years), craniospinal (8.0 years), and all survivors (9.1 years old) in the Childhood Cancer Survivor Study (CCSS) expansion cohort treated with RT. The downscaling was performed using our in-house age scaling functions (ASFs). To geometrically validate the scaling, Dice similarity coefficient (DSC), mean distance to agreement (MDA), and Euclidean distance (ED) were calculated between the scaled and ground-truth discrete-aged phantom (unscaled UF/NCI) for whole-body, brain, heart, liver, pancreas, and kidneys. Additionally, heights of the scaled phantoms were compared with ground-truth phantoms’ height, and the Centers for Disease Control and Prevention (CDC) reported 50th percentile height. Scaled organ masses were compared with ground-truth organ masses. For the dosimetric assessment, one reference size phantom and seventeen body-size dependent 5-year-old phantoms (9 male and 8 female) of varying body mass indices (BMI) were downscaled to 3.9-year-old dimensions for two different radiation dose studies. For the first study, we simulated a 6 MV photon right-sided flank field RT plan on a reference size 5-year-old and 3.9-year-old (both of healthy BMI), keeping the field size the same in both cases. Percent of volume receiving dose ≥15 Gy (V15) and the mean dose were calculated for the pancreas, liver, and stomach. For the second study, the same treatment plan, but with patient anatomy-dependent field sizes, was simulated on seventeen body-size dependent 5- and 3.9-year-old phantoms with varying BMIs. V15, mean dose, and minimum dose received by 1% of the volume (D1), and by 95% of the volume (D95) were calculated for pancreas, liver, stomach, left kidney (contralateral), right kidney, right and left colons, gallbladder, thoracic vertebrae, and lumbar vertebrae. A non-parametric Wilcoxon rank-sum test was performed to determine if the dose to organs of exact age-scaled and nearest age-matched phantoms were significantly different (p < 0.05). Results. In the feasibility study, the best DSCs were obtained for the brain (median: 0.86) and whole-body (median: 0.91) while kidneys (median: 0.58) and pancreas (median: 0.32) showed poorer agreement. In the case of MDA and ED, whole-body, brain, and kidneys showed tighter distribution and lower median values as compared to other organs. For height comparison, the overall agreement was within 2.8% (3.9 cm) and 3.0% (3.2 cm) of ground-truth UF/NCI and CDC reported 50th percentile heights, respectively. For mass comparison, the maximum percent and absolute differences between the scaled and ground-truth organ masses were within 31.3% (29.8 g) and 211.8 g (16.4%), respectively (across all ages). In the first dosimetric study, absolute difference up to 6% and 1.3 Gy was found for V15 and mean dose, respectively. In the second dosimetric study, V15 and mean dose were significantly different (p 1 and D95 were not significantly different for most organs (p > 0.05). Conclusion. We have successfully evaluated our ASFs by scaling UF/NCI computational phantoms from one age to another age, which demonstrates the feasibility of scaling any CT-based anatomy. We have found that dose to organs of exact age-scaled and nearest aged-matched phantoms are significantly different (p < 0.05) which indicates that using the exact age-scaled phantoms for retrospective dosimetric studies is a better approach.
- Published
- 2022
9. Development and validation of an age-scalable cardiac model with substructures for dosimetry in late-effects studies of childhood cancer survivors
- Author
-
James E. Bates, Stephen F Kry, Gregory T. Armstrong, Chelsea C. Pinnix, Ying Qiao, David S Followill, Bradford S. Hoppe, Arnold C. Paulino, Suman Shrestha, Rebecca M. Howell, Aashish C. Gupta, Laurence E. Court, Louis S. Constine, Choonsik Lee, Susan A. Smith, Yutaka Yasui, Rita E. Weathers, and Constance A. Owens
- Subjects
medicine.medical_specialty ,Adolescent ,Overlap coefficient ,medicine.medical_treatment ,Cardiac Volume ,Imaging phantom ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Cancer Survivors ,Neoplasms ,medicine ,Dosimetry ,Humans ,Radiology, Nuclear Medicine and imaging ,Risk factor ,Child ,Radiometry ,Computational phantom ,business.industry ,Phantoms, Imaging ,Late effects ,Infant ,Heart ,Hematology ,Cardiac toxicity ,Radiation therapy ,Oncology ,030220 oncology & carcinogenesis ,Child, Preschool ,Cohort ,Radiology ,business ,Childhood cancer ,Cohort study - Abstract
Background and Purpose Radiation therapy is a risk factor for late cardiac disease in childhood cancer survivors. Several pediatric cohort studies have established whole heart dose and dose–volume response models. Emerging data suggest that dose to cardiac substructures may be more predictive than whole heart metrics. In order to develop substructure dose-response models, the heart model previously used for pediatric cohort dosimetry needed enhancement and substructure delineation. Methods To enhance our heart model, we combined the age-scalable capability of our computational phantom with the anatomically-delineated (with substructures) heart models from an international humanoid phantom series. We examined cardiac volume similarity/overlap between registered age-scaled phantoms (1, 5, 10, and 15 years) with the enhanced heart model and the reference phantoms of the same age; dice similarity coefficient (DSC) and overlap coefficient (OC) were calculated for each matched pair. To assess the accuracy of our enhanced heart model, we compared doses from computed tomography-based planning (ground truth) with reconstructed heart doses. We also compared doses calculated with the prior and enhanced heart models for a cohort of nearly 5000 childhood cancer survivors. Results We developed a realistic cardiac model with 14-substructures, scalable across a broad age range (1–15 years); average DSC and OC were 0.84 ± 0.05 and 0.90 ± 0.05, respectively. The average percent difference between reconstructed and ground truth mean heart doses was 4.2%. In the cohort dosimetry analysis, dose and dose-volume metrics were approximately 10% lower on average when the enhanced heart model was used for dose reconstructions. Conclusion We successfully developed and validated an anatomically realistic age-scalable cardiac model that can be used to establish substructure dose-response models for late cardiac disease in childhood cancer survivor cohorts.
- Published
- 2020
10. Association of Breast Cancer Risk After Childhood Cancer With Radiation Dose to the Breast and Anthracycline Use: A Report From the Childhood Cancer Survivor Study
- Author
-
Rebecca M. Howell, Lindsay M. Morton, Rochelle E. Curtis, Diana R. Withrow, Gregory T. Armstrong, Tara O. Henderson, Chaya S. Moskowitz, Michael Arnold, Kevin C. Oeffinger, John Whitton, Todd M. Gibson, Amy Berrington de Gonzalez, Susan A. Smith, Rita E. Weathers, Joseph P. Neglia, Peter D. Inskip, Lene H.S. Veiga, Lucie M. Turcotte, Wendy M. Leisenring, and Leslie L. Robison
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Canada ,Anthracycline ,Adolescent ,medicine.medical_treatment ,Estrogen receptor ,Breast Neoplasms ,Childhood Cancer Survivor Study ,Radiation Dosage ,Risk Assessment ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Breast cancer ,Risk Factors ,030225 pediatrics ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Child ,Radiation Injuries ,Original Investigation ,Retrospective Studies ,business.industry ,Brain Neoplasms ,Incidence ,Cancer ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Chemotherapy regimen ,United States ,Radiation therapy ,Survival Rate ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,business ,Follow-Up Studies - Abstract
IMPORTANCE: Chest irradiation for childhood cancer is associated with increases in breast cancer risk. Growing evidence suggests that anthracyclines increase this risk, but the outcome of combined anthracycline use and radiotherapy has not been studied. OBJECTIVES: To evaluate breast cancer risk in childhood cancer survivors following radiotherapy and chemotherapy and assess whether risks varied by estrogen receptor (ER) status. DESIGN, SETTING, AND PARTICIPANTS: In a North American hospital-based nested case-control study, a retrospective cohort of 14 358 five-year survivors of childhood cancer, diagnosed from 1970 to 1986 and followed up through December 31, 2016, was analyzed. Cases (n = 271) were defined as women with subsequent breast cancer. Controls (n = 1044) were matched 4:1 to cases by age at first cancer and duration of follow-up (± 2 years). Data analysis was conducted from September 2017 to July 2018. EXPOSURES: Radiation dose to breast tumor site and ovaries and cumulative chemotherapy doses, including anthracyclines and alkylating agents. MAIN OUTCOMES AND MEASURES: Odds ratios (ORs) for subsequent breast cancer by ER status. RESULTS: A total of 271 women served as breast cancer cases (median age at first cancer diagnosis, 15 years [range, 3-20]; median age at breast cancer diagnosis, 39 years [range, 20-57]): 201 invasive (113 ER positive [ER+], 41 ER negative [ER–], and 47 unknown) and 70 in situ breast cancers. The OR for breast cancer increased with increasing radiation dose to the breast (OR per 10 Gy, 3.9; 95% CI, 2.5-6.5) and was similar for ER+ (OR per 10 Gy, 5.5; 95% CI, 2.8-12.6) and ER– (OR per 10 Gy, 4.8; 95% CI, 1.7-22.3) cancers. For women who received ovarian doses less than 1 Gy, the OR per 10 Gy to the breast was higher (OR, 6.8; 95% CI, 3.9-12.5) than for women who received ovarian doses greater than or equal to 15 Gy (OR, 1.4; 95% CI, 1.0-6.4). The OR for breast cancer increased with cumulative anthracycline dose (OR per 100 mg/m(2), 1.23; 95% CI, 1.09-1.39; P
- Published
- 2019
11. Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer
- Author
-
Neige Journy, Sander Roberti, Sara J. Schonfeld, Flora E. van Leeuwen, Rita E. Weathers, Marilyn Stovall, Amy Berrington de Gonzalez, Susan A. Smith, Lindsay M. Morton, Leila Vaalavirta, Ethel S. Gilbert, Michael Hauptmann, Rebecca M. Howell, David R. W. Hodgson, Centre de recherche en épidémiologie et santé des populations (CESP), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
- Subjects
medicine.medical_specialty ,Esophageal Neoplasms ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,Breast Neoplasms ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,medicine ,High doses ,Humans ,Radiology, Nuclear Medicine and imaging ,Survivors ,business.industry ,Cancer ,Hematology ,Second primary cancer ,Odds ratio ,medicine.disease ,Confidence interval ,3. Good health ,Radiation therapy ,Oncology ,030220 oncology & carcinogenesis ,Case-Control Studies ,Cohort ,Female ,Radiology ,Radiotherapy, Conformal ,business - Abstract
Purpose To investigate the relationship between oesophagus dose-volume distribution and long-term risk of oesophageal cancer after radiation therapy for breast cancer. Materials and methods In a case-control study nested within a cohort of 289,748 ≥5-year survivors of female breast cancer treated in 1943–2003 in five countries, doses to the second primary cancer (DSPC) and individual dose-volume histograms (DVH) to the entire oesophagus were reconstructed for 252 oesophageal cancer cases and 488 matched controls (median follow-up time: 13, range: 5–37 years). Using conditional logistic regression, we estimated excess odds ratios (EOR) of oesophageal cancer associated with DVH metrics. We also investigated whether DVH metrics confounded or modified DSPC-related -risk estimates. Results Among the DVH metrics evaluated, median dose (Dmedian) to the entire oesophagus had the best statistical performance for estimating risk of all histological types combined (EOR/Gy = 0.071, 95% confidence interval [CI]: 0.018 to 0.206). For squamous cell carcinoma, the most common subtype, the EOR/Gy for Dmedian increased by 31% (95% CI: 3% to 205%) for each increment of 10% of V30 (p = 0.02). Adjusting for DVH metrics did not materially change the EOR/Gy for DSPC, but there was a borderline significant positive interaction between DSPC and V30 (p = 0.07). Conclusion This first study investigating the relationship between oesophagus dose-volume distribution and oesophageal cancer risk showed an increased risk per Gy for Dmedian with larger volumes irradiated at high doses. While current techniques allows better oesophagus sparing, constraints applied to Dmedian and V30 could potentially further reduce the risk of oesophageal cancer.
- Published
- 2019
12. PO-1330: On the Implementation and Validation of 3D Computational Pediatric Phantoms in Commercial TPS
- Author
-
Susan A. Smith, Aashish C. Gupta, Suman Shrestha, Constance A. Owens, C. Ditty, Choonik Lee, Ying Qiao, Rita E. Weathers, and Rebecca M. Howell
- Subjects
Oncology ,Radiology, Nuclear Medicine and imaging ,Hematology - Published
- 2020
13. Increased pancreatic cancer risk following radiotherapy for testicular cancer
- Author
-
Sophie D. Fosså, Eric J. Holowaty, Charles F. Lynch, Michael Andersson, Tom Børge Johannesen, Alexandra W. van den Belt-Dusebout, Joseph F. Fraumeni, Hans H. Storm, Flora E. van Leeuwen, Michael Hauptmann, Marilyn Stovall, Rita E. Weathers, Magnus Kaijser, Lindsay M. Morton, Ethel S. Gilbert, Per Hall, Lois B. Travis, Heikki Joensuu, Eero Pukkala, Berthe M.P. Aleman, Ruth A. Kleinerman, Rochelle E. Curtis, Preetha Rajaraman, Leila Vaalavirta, Susan A. Smith, Frøydis Langmark, and Graça M. Dores
- Subjects
Male ,Organs at Risk ,0301 basic medicine ,Oncology ,Cancer Research ,Neoplasms, Radiation-Induced ,Epidemiology ,medicine.medical_treatment ,pancreatic cancer ,chemotherapy ,0302 clinical medicine ,Cumulative incidence ,Young adult ,Neoplasms, Second Primary ,Radiotherapy Dosage ,Middle Aged ,Combined Modality Therapy ,testicular cancer ,3. Good health ,medicine.anatomical_structure ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Pancreas ,Adult ,Risk ,medicine.medical_specialty ,Young Adult ,03 medical and health sciences ,Testicular Neoplasms ,Pancreatic cancer ,Internal medicine ,medicine ,Humans ,radiotherapy ,Testicular cancer ,Aged ,Chemotherapy ,business.industry ,logistic regression ,Dose-Response Relationship, Radiation ,Odds ratio ,medicine.disease ,Pancreatic Neoplasms ,Radiation therapy ,030104 developmental biology ,Case-Control Studies ,business ,Orchiectomy - Abstract
Background: Pancreatic cancer risk is elevated among testicular cancer (TC) survivors. However, the roles of specific treatments are unclear. Methods: Among 23 982 5-year TC survivors diagnosed during 1947–1991, doses from radiotherapy to the pancreas were estimated for 80 pancreatic cancer patients and 145 matched controls. Chemotherapy details were recorded. Logistic regression was used to estimate odds ratios (ORs). Results: Cumulative incidence of second primary pancreatic cancer was 1.1% at 30 years after TC diagnosis. Radiotherapy (72 (90%) cases and 115 (80%) controls) was associated with a 2.9-fold (95% confidence interval (CI) 1.0–7.8) increased risk. The OR increased linearly by 0.12 per Gy to the pancreas (P-trend
- Published
- 2016
14. The Risk of Cataract among Survivors of Childhood and Adolescent Cancer: A Report from the Childhood Cancer Survivor Study
- Author
-
Susan A. Smith, Leslie L. Robison, Alice J. Sigurdson, Lene H.S. Veiga, Ann C. Mertens, Marilyn Stovall, Peter D. Inskip, Rita E. Weathers, Charles A. Sklar, Gabriel Chodick, Ruth A. Kleinerman, and Wendy M. Leisenring
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Adolescent cancer ,Biophysics ,Childhood Cancer Survivor Study ,Logistic regression ,Cataract ,Article ,030218 nuclear medicine & medical imaging ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cataracts ,Neoplasms ,Lens, Crystalline ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Survivors ,Young adult ,Child ,Radiation Injuries ,Models, Statistical ,Radiation ,business.industry ,Cancer ,Dose-Response Relationship, Radiation ,Middle Aged ,medicine.disease ,Surgery ,Radiation therapy ,030220 oncology & carcinogenesis ,Cohort ,Female ,business - Abstract
With therapeutic successes and improved survival after a cancer diagnosis in childhood, increasing numbers of cancer survivors are at risk of subsequent treatment-related morbidities, including cataracts. While it is well known that the lens of the eye is one of the most radiosensitive tissues in the human body, the risks associated with radiation doses less than 2 Gy are less understood, as are the long- and short-term cataract risks from exposure to ionizing radiation at a young age. In this study, we followed 13,902 five-year survivors of childhood cancer in the Childhood Cancer Survivor Study cohort an average of 21.4 years from the date of first cancer diagnosis. For patients receiving radiotherapy, lens dose (mean: 2.2 Gy; range: 0–66 Gy) was estimated based on radiotherapy records. We used unconditional multivariable logistic regression models to evaluate prevalence of self-reported cataract in relationship to cumulative radiation dose both at five years after the initial cancer diagnosis and at the end of follow-up. We modeled the radiation effect in terms of the excess odds ratio (EOR) per Gy. We also analyzed cataract incidence starting from five years after initial cancer diagnosis to the end of follow-up using Cox regression. A total of 483 (3.5%) cataract cases were identified, including 200 (1.4%) diagnosed during the first five years of follow-up. In a multivariable logistic regression model, cataract prevalence at the end of follow-up was positively associated with lens dose in a manner consistent with a linear dose-response relationship (EOR per Gy = 0.92; 95% CI: 0.65–1.20). The odds ratio for doses between 0.5 and 1.5 Gy was elevated significantly relative to doses
- Published
- 2016
15. Breast cancer following spinal irradiation for a childhood cancer: A report from the Childhood Cancer Survivor Study
- Author
-
Gregory T. Armstrong, Rita E. Weathers, Suzanne L. Wolden, Marilyn Stovall, Kevin C. Oeffinger, Chaya S. Moskowitz, Joseph P. Neglia, Leslie L. Robison, Joanne F. Chou, Wendy M. Leisenring, and Jyoti Malhotra
- Subjects
Risk ,Oncology ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,Adolescent ,Central nervous system ,Breast Neoplasms ,Childhood Cancer Survivor Study ,Article ,Craniospinal Irradiation ,Central Nervous System Neoplasms ,Breast cancer ,Internal medicine ,Epidemiology of cancer ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Survivors ,Child ,Leukemia ,business.industry ,Infant, Newborn ,Infant ,Cancer ,Neoplasms, Second Primary ,Radiotherapy Dosage ,Hematology ,medicine.disease ,United States ,medicine.anatomical_structure ,Child, Preschool ,Cohort ,Female ,business - Abstract
It has been suggested that pediatric patients treated with spinal irradiation may have an elevated risk of breast cancer. Among a cohort of 363 long-term survivors of a pediatric central nervous system tumor or leukemia treated with spinal irradiation, there was little evidence of an increased breast cancer risk.
- Published
- 2015
16. Development of an age-scalable 3D computational phantom in DICOM standard for late effects studies of childhood cancer survivors
- Author
-
Stephen F Kry, Susan A. Smith, Peter A Balter, Suman Shrestha, Aashish C. Gupta, Constance A. Owens, Rita E. Weathers, Rebecca M. Howell, and Ying Qiao
- Subjects
Adult ,Male ,Adolescent ,Computer science ,Fortran ,0206 medical engineering ,Childhood cancer ,Population ,02 engineering and technology ,dose reconstruction ,Wilms Tumor ,Article ,World health ,Imaging phantom ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,DICOM ,0302 clinical medicine ,Cancer Survivors ,late effects ,Humans ,Child ,Radiometry ,education ,Dicom Standard ,General Nursing ,Retrospective Studies ,computer.programming_language ,education.field_of_study ,Phantoms, Imaging ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Infant, Newborn ,Infant ,equipment and supplies ,020601 biomedical engineering ,Kidney Neoplasms ,United States ,computational phantoms ,Child, Preschool ,pediatric phantoms ,Female ,Body region ,Nuclear medicine ,business ,computer - Abstract
Purpose: We previously developed an age-scalable 3D computational phantom that has been widely used for retrospective whole-body dose reconstructions of conventional two-dimensional historic radiation therapy (RT) treatments in late effects studies of childhood cancer survivors. This phantom is modeled in the FORTRAN programming language and is not readily applicable for dose reconstructions for survivors treated with contemporary RT whose treatment plans were designed using computed tomography images and complex treatment fields. The goal of this work was to adapt the current FORTRAN model of our age-scalable computational phantom into Digital Imaging and Communications in Medicine (DICOM) standard so that it can be used with any treatment planning system (TPS) to reconstruct contemporary RT. Additionally, we report a detailed description of the phantom’s age-based scaling functions, information that was not previously published. Method: We developed a Python script that adapts our phantom model from FORTRAN to DICOM. To validate the conversion, we compared geometric parameters for the phantom modeled in FORTRAN and DICOM scaled to ages 1 month, 6 months, 1, 2, 3, 5, 8, 10, 15, and 18 years. Specifically, we calculated the percent differences between the corner points and volume of each body region and the normalized mean square distance (NMSD) between each of the organs. In addition, we also calculated the percent difference between the heights of our DICOM age-scaled phantom and the heights (50th percentile) reported by the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) for male and female children of the same ages. Additionally, we calculated the difference between the organ masses for our DICOM phantom and the organ masses for two reference phantoms (from International Comission on Radiation Protection (ICRP) 89 and the University of Florida/National Cancer Institute reference hybrid voxel phantoms) for ages newborn, 1, 5, 10, 15 and adult. Lastly, we conducted a feasibility study using our DICOM phantom for organ dose calculations in a commercial TPS. Specifically, we simulated a 6 MV photon right-sided flank field RT plan for our DICOM phantom scaled to age 3.9 years; treatment field parameters and age were typical of a Wilms tumor RT treatment in the Childhood Cancer Survivor Study. For comparison, the same treatment was simulated using our in-house dose calculation system with our FORTRAN phantom. The percent differences (between FORTRAN and DICOM) in mean dose and percent of volume receiving dose ≥5 Gy were calculated for two organs at risk, liver and pancreas. Results: The percent differences in corner points and the volumes of head, neck, and trunk body regions between our phantom modeled in FORTRAN and DICOM agreed within 3%. For all of the ages, the NMSDs were negliglible with a maximum NMSD of 7.80 × 10 − 2 mm for occiptital lobe of 1 month. The heights of our age-scaled phantom agreed with WHO/CDC data within 7% from infant to adult, and within 2% agreement for ages 5 years and older. We observed that organ masses in our phantom are less than the organ masses for other reference phantoms. Dose calculations done with our in-house calculation system (with FORTRAN phantom) and commercial TPS (with DICOM phantom) agreed within 7%. Conclusion: We successfully adapted our phantom model from the FORTRAN language to DICOM standard and validated its geometric consistency. We also demonstrated that our phantom model is representative of population height data for infant to adult, but that the organ masses are smaller than in other reference phantoms and need further refinement. Our age-scalable computational phantom modeled in DICOM standard can be scaled to any age at RT and used within a commercial TPS to retrospectively reconstruct doses from contemporary RT in childhood cancer survivors.
- Published
- 2020
17. Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
- Author
-
Charles A. Sklar, Arin L. Madenci, Wendy M. Leisenring, Stacey Fisher, Gregory T. Armstrong, Lisa Diller, Rita E. Weathers, Yutaka Yasui, Kevin C. Oeffinger, Marilyn Stovall, Leslie L. Robison, Robert E. Goldsby, and Christopher B. Weldon
- Subjects
Adult ,Male ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Clinical Sciences ,Oncology and Carcinogenesis ,Childhood Cancer Survivor Study ,Cohort Studies ,Rare Diseases ,7.1 Individual care needs ,Clinical Research ,Neoplasms ,medicine ,Humans ,Cumulative incidence ,Survivors ,Oncology & Carcinogenesis ,Sibling ,Child ,Preschool ,Cancer ,Chemotherapy ,business.industry ,Incidence ,Prevention ,Incidence (epidemiology) ,Infant, Newborn ,Infant ,ORIGINAL REPORTS ,Newborn ,medicine.disease ,Radiation therapy ,Oncology ,Child, Preschool ,Female ,Management of diseases and conditions ,Digestive Diseases ,business ,Intestinal Obstruction ,Cohort study - Abstract
Purpose For adult survivors of childhood cancer, knowledge about the long-term risk of intestinal obstruction from surgery, chemotherapy, and radiotherapy is limited. Methods Intestinal obstruction requiring surgery (IOS) occurring 5 or more years after cancer diagnosis was evaluated in 12,316 5-year survivors in the Childhood Cancer Survivor Study (2,002 with and 10,314 without abdominopelvic tumors) and 4,023 sibling participants. Cumulative incidence of IOS was calculated with second malignant neoplasm, late recurrence, and death as competing risks. Using piecewise exponential models, we assessed the associations of clinical and demographic factors with rate of IOS. Results Late IOS was reported by 165 survivors (median age at IOS, 19 years; range, 5 to 50 years; median time from diagnosis to IOS, 13 years) and 14 siblings. The cumulative incidence of late IOS at 35 years was 5.8% (95% CI, 4.4% to 7.3%) among survivors with abdominopelvic tumors, 1.0% (95% CI, 0.7% to 1.4%) among those without abdominopelvic tumors, and 0.3% (95% CI, 0.1% to 0.5%) among siblings. Among survivors, abdominopelvic tumor (adjusted rate ratio [ARR], 3.6; 95% CI, 1.9 to 6.8; P < .001) and abdominal/pelvic radiotherapy within 5 years of cancer diagnosis (ARR, 2.4; 95% CI, 1.6 to 3.7; P < .001) increased the rate of late IOS, adjusting for diagnosis year; sex; race/ethnicity; age at diagnosis; age during follow-up (as natural cubic spline); cancer type; and chemotherapy, radiotherapy, and surgery within 5 years of cancer diagnosis. Developing late IOS increased subsequent mortality among survivors (ARR, 1.8; 95% CI, 1.1 to 2.9; P = .016), adjusting for the same factors. Conclusion The long-term risk of IOS and its association with subsequent mortality underscore the need to promote awareness of this complication among patients and providers.
- Published
- 2015
18. Recurrent stroke in childhood cancer survivors
- Author
-
Kevin R. Krull, L. L. Robison, Sabine Mueller, Greg Armstrong, Rita E. Weathers, Marilyn Stovall, Heather J. Fullerton, Kayla Stratton, Wendy W. Leisenring, Robert E. Goldsby, and Charles A. Sklar
- Subjects
Male ,Aging ,Pediatrics ,Cohort Studies ,Recurrence ,Neoplasms ,Cumulative incidence ,Longitudinal Studies ,Survivors ,Child ,Stroke ,Cancer ,Pediatric ,education.field_of_study ,Rehabilitation ,Hazard ratio ,Middle Aged ,Child, Preschool ,Female ,Cognitive Sciences ,Adult ,Pediatric Research Initiative ,medicine.medical_specialty ,Adolescent ,Pediatric Cancer ,Clinical Sciences ,Population ,Article ,Young Adult ,medicine ,Humans ,cardiovascular diseases ,Risk factor ,Preschool ,education ,Retrospective Studies ,Neurology & Neurosurgery ,Proportional hazards model ,business.industry ,Prevention ,Neurosciences ,Infant ,Retrospective cohort study ,medicine.disease ,Pediatric cancer ,Brain Disorders ,Neurology (clinical) ,business ,Follow-Up Studies ,2.4 Surveillance and distribution - Abstract
ObjectiveTo estimate the rates and predictors of recurrent stroke among survivors of pediatric cancer who have had a first stroke.MethodsThe Childhood Cancer Survivor Study is a retrospective cohort study with longitudinal follow-up that enrolled 14,358 survivors (
- Published
- 2015
19. Individual Prediction of Heart Failure Among Childhood Cancer Survivors
- Author
-
Daniel M. Green, Daniel A. Mulrooney, Elizabeth A.M. Feijen, Helena J.H. van der Pal, Gregory T. Armstrong, Lillian R. Meacham, Kevin C. Oeffinger, Kirsten K. Ness, William L. Border, Rita E. Weathers, Marilyn Stovall, Charles A. Sklar, Eric J. Chow, Leslie L. Robison, Yutaka Yasui, Melissa M. Hudson, Yan Chen, Kathleen Meeske, Norman E. Breslow, Leontien C. M. Kremer, CCA -Cancer Center Amsterdam, ARD - Amsterdam Reproduction and Development, Paediatric Oncology, and APH - Amsterdam Public Health
- Subjects
Adult ,Male ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Antineoplastic Agents ,Disease ,Childhood Cancer Survivor Study ,Risk Assessment ,Cohort Studies ,Young Adult ,Risk Factors ,Neoplasms ,medicine ,Humans ,Poisson Distribution ,Survivors ,Young adult ,Child ,Netherlands ,Heart Failure ,Heart transplantation ,Radiotherapy ,business.industry ,Incidence ,Reproducibility of Results ,Cancer ,medicine.disease ,Oncology ,Area Under Curve ,Child, Preschool ,Heart failure ,North America ,Female ,business ,Risk assessment ,Cohort study - Abstract
Purpose To create clinically useful models that incorporate readily available demographic and cancer treatment characteristics to predict individual risk of heart failure among 5-year survivors of childhood cancer. Patients and Methods Survivors in the Childhood Cancer Survivor Study (CCSS) free of significant cardiovascular disease 5 years after cancer diagnosis (n = 13,060) were observed through age 40 years for the development of heart failure (ie, requiring medications or heart transplantation or leading to death). Siblings (n = 4,023) established the baseline population risk. An additional 3,421 survivors from Emma Children's Hospital (Amsterdam, the Netherlands), the National Wilms Tumor Study, and the St Jude Lifetime Cohort Study were used to validate the CCSS prediction models. Results Heart failure occurred in 285 CCSS participants. Risk scores based on selected exposures (sex, age at cancer diagnosis, and anthracycline and chest radiotherapy doses) achieved an area under the curve of 0.74 and concordance statistic of 0.76 at or through age 40 years. Validation cohort estimates ranged from 0.68 to 0.82. Risk scores were collapsed to form statistically distinct low-, moderate-, and high-risk groups, corresponding to cumulative incidences of heart failure at age 40 years of 0.5% (95% CI, 0.2% to 0.8%), 2.4% (95% CI, 1.8% to 3.0%), and 11.7% (95% CI, 8.8% to 14.5%), respectively. In comparison, siblings had a cumulative incidence of 0.3% (95% CI, 0.1% to 0.5%). Conclusion Using information available to clinicians soon after completion of childhood cancer therapy, individual risk for subsequent heart failure can be predicted with reasonable accuracy and discrimination. These validated models provide a framework on which to base future screening strategies and interventions.
- Published
- 2015
20. Pancreatic cancer risk after treatment of Hodgkin lymphoma
- Author
-
Per Hall, Sophie D. Fosså, Joseph F. Fraumeni, Lois B. Travis, S. A. Smith, Marilyn Stovall, Tom Børge Johannesen, Eero Pukkala, Hans H. Storm, Michael Andersson, Rochelle E. Curtis, Berthe M.P. Aleman, Ruth A. Kleinerman, Lindsay M. Morton, F.E. van Leeuwen, Eric J. Holowaty, Heikki Joensuu, Charles F. Lynch, Ethel S. Gilbert, Magnus Kaijser, Rita E. Weathers, David C. Hodgson, Leila Vaalavirta, Frøydis Langmark, and Graça M. Dores
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,medicine.medical_treatment ,Risk Factors ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Pancreatic cancer ,medicine ,Humans ,Aged ,Chemotherapy ,Radiotherapy ,business.industry ,Case-control study ,Cancer ,Dose-Response Relationship, Radiation ,Original Articles ,Hematology ,Middle Aged ,medicine.disease ,Hodgkin Disease ,Chemotherapy regimen ,Pancreatic Neoplasms ,Radiation therapy ,Case-Control Studies ,Hodgkin lymphoma ,Female ,business ,After treatment - Abstract
Although elevated risks of pancreatic cancer have been observed in long-term survivors of Hodgkin lymphoma (HL), no prior study has assessed the risk of second pancreatic cancer in relation to radiation dose and specific chemotherapeutic agents.We conducted an international case-control study within a cohort of 19 882 HL survivors diagnosed from 1953 to 2003 including 36 cases and 70 matched controls.Median ages at HL and pancreatic cancer diagnoses were 47 and 60.5 years, respectively; median time to pancreatic cancer was 19 years. Pancreatic cancer risk increased with increasing radiation dose to the pancreatic tumor location (Ptrend = 0.005) and increasing number of alkylating agent (AA)-containing cycles of chemotherapy (Ptrend = 0.008). The odds ratio (OR) for patients treated with both subdiaphragmatic radiation (≥10 Gy) and ≥6 AA-containing chemotherapy cycles (13 cases, 6 controls) compared with patients with neither treatment was 17.9 (95% confidence interval 3.5-158). The joint effect of these two treatments was significantly greater than additive (P = 0.041) and nonsignificantly greater than multiplicative (P = 0.29). Especially high risks were observed among patients receiving ≥8400 mg/m(2) of procarbazine with nitrogen mustard or ≥3900 mg/m(2) of cyclophosphamide.Our study demonstrates for the first time that both radiotherapy and chemotherapy substantially increase pancreatic cancer risks among HL survivors treated in the past. These findings extend the range of nonhematologic cancers associated with chemotherapy and add to the evidence that the combination of radiotherapy and chemotherapy can lead to especially large risks.
- Published
- 2014
21. Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015
- Author
-
Gregory T. Armstrong, Michael Arnold, Todd M. Gibson, Rita E. Weathers, Lucie M. Turcotte, Yutaka Yasui, Leslie L. Robison, Qi Liu, Joseph P. Neglia, Rebecca M. Howell, Susan A. Smith, Sue Hammond, Wendy M. Leisenring, and Tara O. Henderson
- Subjects
Adult ,Male ,medicine.medical_specialty ,Canada ,Neoplasms, Radiation-Induced ,Time Factors ,Adolescent ,medicine.medical_treatment ,Antineoplastic Agents ,Lower risk ,Risk Assessment ,Article ,03 medical and health sciences ,0302 clinical medicine ,Interquartile range ,Internal medicine ,Neoplasms ,Medicine ,Humans ,Cumulative incidence ,030212 general & internal medicine ,Survivors ,Child ,Retrospective Studies ,business.industry ,Incidence (epidemiology) ,Cancer ,Retrospective cohort study ,Neoplasms, Second Primary ,General Medicine ,medicine.disease ,United States ,Surgery ,Radiation therapy ,030220 oncology & carcinogenesis ,Female ,Skin cancer ,business - Abstract
Cancer treatments are associated with subsequent neoplasms in survivors of childhood cancer. It is unknown whether temporal changes in therapy are associated with changes in subsequent neoplasm risk.To quantify the association between temporal changes in treatment dosing and subsequent neoplasm risk.Retrospective, multicenter cohort study of 5-year cancer survivors diagnosed before age 21 years from pediatric tertiary hospitals in the United States and Canada between 1970-1999, with follow-up through December 2015.Radiation and chemotherapy dose changes over time.Subsequent neoplasm 15-year cumulative incidence, cumulative burden, and standardized incidence ratios for subsequent malignancies, compared by treatment decade. Multivariable models assessed relative rates (RRs) of subsequent neoplasms by 5-year increments, adjusting for demographic and clinical characteristics. Mediation analyses assessed whether changes in rates of subsequent neoplasms over time were mediated by treatment variable modifications.Among 23 603 survivors of childhood cancer (mean age at diagnosis, 7.7 years; 46% female) the most common initial diagnoses were acute lymphoblastic leukemia, Hodgkin lymphoma, and astrocytoma. During a mean follow-up of 20.5 years (374 638 person-years at risk), 1639 survivors experienced 3115 subsequent neoplasms, including 1026 malignancies, 233 benign meningiomas, and 1856 nonmelanoma skin cancers. The most common subsequent malignancies were breast and thyroid cancers. Proportions of individuals receiving radiation decreased (77% for 1970s vs 33% for 1990s), as did median dose (30 Gy [interquartile range, 24-44] for 1970s vs 26 Gy [interquartile range, 18-45] for 1990s). Fifteen-year cumulative incidence of subsequent malignancies decreased by decade of diagnosis (2.1% [95% CI, 1.7%-2.4%] for 1970s, 1.7% [95% CI, 1.5%-2.0%] for 1980s, 1.3% [95% CI, 1.1%-1.5%] for 1990s). Reference absolute rates per 1000 person-years were 1.12 (95% CI, 0.84-1.57) for subsequent malignancies, 0.16 (95% CI, 0.06-0.41) for meningiomas, and 1.71 (95% CI, 0.88-3.33) for nonmelanoma skin cancers for survivors with reference characteristics (no chemotherapy, splenectomy, or radiation therapy; male; attained age 28 years). Standardized incidence ratios declined for subsequent malignancies over treatment decades, with advancing attained age. Relative rates declined with each 5-year increment for subsequent malignancies (RR, 0.87 [95% CI, 0.82-0.93]; P .001), meningiomas (RR, 0.85 [95% CI, 0.75-0.97]; P = .03), and nonmelanoma skin cancers (RR, 0.75 [95% CI, 0.67-0.84]; P .001). Radiation dose changes were associated with reduced risk for subsequent malignancies, meningiomas, and nonmelanoma skin cancers.Among survivors of childhood cancer, the risk of subsequent malignancies at 15 years after initial cancer diagnosis remained increased for those diagnosed in the 1990s, although the risk was lower compared with those diagnosed in the 1970s. This lower risk was associated with reduction in therapeutic radiation dose.
- Published
- 2017
22. Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects
- Author
-
Ethel S. Gilbert, Preetha Rajaraman, Marilyn Stovall, Eero Pukkala, Rochelle E. Curtis, Rita E. Weathers, Heikki Joensuu, Sophie D. Fosså, Ruth A. Kleinerman, Hans H. Storm, Joseph F. Fraumeni, Tom Børge Johannesen, Michael Andersson, Flora E. van Leeuwen, Michael Hauptmann, Eric J. Holowaty, Berthe M.P. Aleman, Lois B. Travis, Magnus Kaijser, David C. Hodgson, Leila Vaalavirta, Susan A. Smith, Alexandra W. van den Belt-Dusebout, Lindsay M. Morton, Frøydis Langmark, Per Hall, Graça M. Dores, and Charles F. Lynch
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Internationality ,Neoplasms, Radiation-Induced ,Adolescent ,medicine.medical_treatment ,Biophysics ,Uterine Cervical Neoplasms ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Testicular Neoplasms ,Stomach Neoplasms ,Internal medicine ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Stomach cancer ,Child ,Testicular cancer ,Aged ,Cervical cancer ,Aged, 80 and over ,Radiation ,business.industry ,Stomach ,Dose fractionation ,Dose-Response Relationship, Radiation ,Odds ratio ,Middle Aged ,medicine.disease ,Hodgkin Disease ,Confidence interval ,Radiation therapy ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,Dose Fractionation, Radiation ,business - Abstract
To further understand the risk of stomach cancer after fractionated high-dose radiotherapy, we pooled individual-level data from three recent stomach cancer case-control studies. These studies were nested in cohorts of five-year survivors of first primary Hodgkin lymphoma (HL), testicular cancer (TC) or cervical cancer (CX) from seven countries. Detailed data were abstracted from patient records and radiation doses were reconstructed to the site of the stomach cancer for cases and to the corresponding sites for matched controls. Among 327 cases and 678 controls, mean doses to the stomach were 15.3 Gy, 24.7 Gy and 1.9 Gy, respectively, for Hodgkin lymphoma, testicular cancer and cervical cancer survivors, with an overall mean dose of 10.3 Gy. Risk increased with increasing radiation dose to the stomach cancer site (P < 0.001) with no evidence of nonlinearity or of a downturn at the highest doses (≥35 Gy). The pooled excess odds ratio per Gy (EOR/Gy) was 0.091 [95% confidence interval (CI): 0.036-0.20] with estimates of 0.049 (95% CI: 0.007-0.16) for Hodgkin lymphoma, 0.27 (95% CI: 0.054-1.44) for testicular cancer and 0.096 (95% CI: -0.002-0.39) for cervical cancer (P homogeneity = 0.25). The EOR/Gy increased with time since exposure (P trend = 0.004), with an EOR/Gy of 0.38 (95% CI: 0.12-1.04) for stomach cancer occurring ≥20 years postirradiation corresponding to odds ratios of 4.8 and 10.5 at radiation doses to the stomach of 10 and 25 Gy, respectively. Of 111 stomach cancers occurring ≥20 years after radiotherapy, 63.8 (57%) could be attributed to radiotherapy. Our findings differ from those based on Japanese atomic-bomb survivors, where the overall EOR/Gy was higher and where there was no evidence of an increase with time since exposure. By pooling data from three studies, we demonstrated a clear increase in stomach cancer risk over a wide range of doses from fractionated radiotherapy with the highest risks occurring many years after exposure. These findings highlight the need to directly evaluate the health effects of high-dose fractionated radiotherapy rather than relying on the data of persons exposed at low and moderate acute doses.
- Published
- 2017
23. Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma
- Author
-
Michael Andersson, Flora E. van Leeuwen, Hans H. Storm, Heikki Joensuu, Magnus Kaijser, Susan A. Smith, Lois B. Travis, Ruth A. Kleinerman, David C. Hodgson, Per Hall, Joseph F. Fraumeni, Ethel S. Gilbert, Frøydis Langmark, Eric J. Holowaty, Charles F. Lynch, Steven L. Simon, Graça M. Dores, Rita E. Weathers, Berthe M.P. Aleman, Eero Pukkala, Tom Børge Johannesen, Marilyn Stovall, Stephanie Lamart, Sophie D. Fosså, Lindsay M. Morton, Leila Vaalavirta, and Rochelle E. Curtis
- Subjects
Risk ,Oncology ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,Esophageal Neoplasms ,Radiotherapy ,Relative survival ,business.industry ,medicine.medical_treatment ,Neoplasms, Second Primary ,Hematology ,Esophageal cancer ,medicine.disease ,Hodgkin Disease ,Radiation therapy ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Hodgkin lymphoma ,Online Only Articles ,Adverse effect ,business - Abstract
Advances in Hodgkin lymphoma (HL) treatment have dramatically improved prognosis, with 5-year relative survival now over 80% in the United States (US) and Europe. However, subsequent malignancies, often occurring as late adverse effects of treatment, are a leading cause of morbidity and mortality
- Published
- 2014
24. EP-2206: Global findings of remote beam output audits; a review by the Global Harmonisation Group
- Author
-
Rita E. Weathers, Tomislav Bokulić, Andrea Molineu, Paige A. Taylor, Mitsuhiro Nakamura, David S Followill, Paola Alvarez, Roger W. Howell, Stephen F Kry, Catharine H. Clark, C. Hurksman, Joanna Izewska, Ivan Williams, Christine B. Peterson, Pavel Kazantsev, Jessica Lye, Andrew Alves, J. Leif, and J. Palmer
- Subjects
medicine.medical_specialty ,Oncology ,Computer science ,Group (periodic table) ,medicine ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Hematology ,Audit ,Beam (structure) - Published
- 2018
25. Genome-Wide Association Study in Irradiated Childhood Cancer Survivors Identifies HTR2A for Subsequent Basal Cell Carcinoma
- Author
-
Gregory T. Armstrong, Lindsay M. Morton, Smita Bhatia, Carmen L. Wilson, Belynda Hicks, Zhaoming Wang, Leslie L. Robison, Yutaka Yasui, Michael Arnold, Wendy M. Leisenring, Shengchao Alfred Li, Stephen J. Chanock, Rita E. Weathers, Rebecca M. Howell, Margaret A. Tucker, Melissa M. Hudson, Casey L. Dagnall, Matthew J. Ehrhardt, Kyla Shelton, Susan A. Smith, Yadav Sapkota, Lucie M. Turcotte, Joshua N. Sampson, Qi Liu, Jinghui Zhang, Joseph P. Neglia, and Eric Karlins
- Subjects
Adult ,Male ,Neoplasms, Radiation-Induced ,Skin Neoplasms ,Adolescent ,Genome-wide association study ,Single-nucleotide polymorphism ,Dermatology ,Childhood Cancer Survivor Study ,Polymorphism, Single Nucleotide ,Biochemistry ,Linkage Disequilibrium ,Article ,Young Adult ,Text mining ,Cancer Survivors ,Neoplasms ,medicine ,Humans ,SNP ,Receptor, Serotonin, 5-HT2A ,Basal cell carcinoma ,Prospective Studies ,Child ,Molecular Biology ,Retrospective Studies ,Skin ,Genetics ,business.industry ,Hazard ratio ,Cell Biology ,Middle Aged ,medicine.disease ,Minor allele frequency ,Carcinoma, Basal Cell ,Genetic Loci ,Child, Preschool ,Female ,business ,Follow-Up Studies ,Genome-Wide Association Study - Published
- 2019
26. Adaptations to a Generalized Radiation Dose Reconstruction Methodology for Use in Epidemiologic Studies: An Update from the MD Anderson Late Effect Group
- Author
-
Marilyn Stovall, Susan A. Smith, Stephen F Kry, Rita E. Weathers, and Rebecca M. Howell
- Subjects
medicine.medical_specialty ,Future studies ,medicine.medical_treatment ,Biophysics ,Radiation Dosage ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Epidemiology ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Radiation ,Phantoms, Imaging ,business.industry ,Late effect ,Radiation Exposure ,Radiation dose reconstruction ,Reconstruction method ,Radiation therapy ,Radiation exposure ,Epidemiologic Studies ,Organ Specificity ,030220 oncology & carcinogenesis ,medicine.symptom ,business - Abstract
Epidemiologic studies that include patients who underwent radiation therapy for the treatment of cancer aim to quantify the relationship between radiotherapy and the risk of subsequent late effects. Because of the long follow-up period required to observe late effects, these studies are conducted retrospectively. The studies routinely include patients treated across numerous institutions using a wide range of technologies and represent treatments over several decades. As a result, determining the dose throughout the patient's body is uniquely challenging. Therefore, estimating doses throughout the patient's body for epidemiologic studies requires special methodologies that are generally applied to a wide range of radiotherapy techniques. Over ten years ago, the MD Anderson Late Effects Group described various dose reconstruction methods for therapeutic and diagnostic radiation exposure for epidemiologic studies. Here we provide an update to the most widely used dose reconstruction methodology for epidemiologic studies, analytical model calculations combined with a 3D age-specific computational phantom. In particular, we describe the various adaptations (and enhancements) of that methodology, as well as how they have been used in radiation epidemiology studies and may be used in future studies.
- Published
- 2019
27. Combined effect of radiotherapy and anthracyclines on risk of breast cancer among female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS)
- Author
-
Rebecca M. Howell, Lucie M. Turcotte, Kevin C. Oeffinger, Gregory T. Armstrong, Peter D. Inskip, Rochelle E. Curtis, Chaya S. Moskowitz, John Whitton, Lene H.S. Veiga, Lindsay M. Morton, Michael Arnold, Amy Berrington de Gonzalez, Todd M. Gibson, Leslie L. Robison, Susan A. Smith, Diana R. Withrow, Wendy M. Leisenring, Tara O. Henderson, Joseph Philip Neglia, and Rita E. Weathers
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Childhood cancer ,Childhood Cancer Survivor Study ,medicine.disease ,Radiation therapy ,Breast cancer ,Internal medicine ,medicine ,Risk factor ,business - Abstract
10053 Background: Breast cancer is a common late-effect for female childhood cancer survivors and chest radiotherapy is an established risk factor. Recent findings showed that treatment with anthracyclines also increases breast cancer risk. However, the risk from the combined effect of radiotherapy and anthracyclines is unknown. Methods: We conducted a matched case-control study of 271 subsequent breast cancer and 1044 controls nested within the CCSS - a North-American cohort of five-year survivors of childhood cancer, diagnosed from 1970-1986 and followed-up through 2016. Detailed treatment records were abstracted to estimate radiation dose (Gy) to the breast cancer location and ovaries and calculate cumulative chemotherapy doses (mg/m2). Multivariable conditional logistic regression was used to estimate Odds ratios (OR) and 95% confidence intervals (CI). Results: Breast cancer risk increased linearly with radiation dose to the breast (OR per 10Gy = 3.9, 95%CI:2.5-6.5) and decreased with increasing ovarian dose (p < 0.01). Adjusted for radiation dose, the highest quartile of dose (455+mg/m2) of anthracyclines was associated with a 3.8-fold increased risk of breast cancer (95%CI:1.8-8.2) compared to no anthracyclines. This risk increased with cumulative anthracycline dose (p-trend < 0.01) and was non-significantly higher for ER+ than ER- breast cancers. For a breast dose of 10+Gy, the OR was 19.1 (95%CI:7.6-48.0) with anthracyclines versus 9.6 (95%CI:4.4-20.7) without anthracyclines, compared to 0- < 1Gy breast dose and no anthracyclines (p-additive interaction = 0.04). Conclusions: The combination of anthracyclines and radiotherapy doses to the breast can markedly increase breast cancer risk compared to those who receive neither treatment. Our results can be used to inform risk management for childhood cancer patients treated in the past, as well as project potential breast cancer risk from current treatment protocols.
- Published
- 2019
28. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort
- Author
-
Sara E. Barton, Rita E. Weathers, Wendy M. Leisenring, Elizabeth S. Ginsburg, Julie Najita, Lisa Diller, Marilyn Stovall, Leslie L. Robison, and Charles A. Sklar
- Subjects
Adult ,Infertility ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Pregnancy Rate ,Childhood Cancer Survivor Study ,Cohort Studies ,Young Adult ,Pregnancy ,Risk Factors ,Neoplasms ,Surveys and Questionnaires ,medicine ,Humans ,Survivors ,Fertility preservation ,Young adult ,Child ,business.industry ,Siblings ,Infant, Newborn ,Infant ,Achievement ,Prognosis ,medicine.disease ,Survival Rate ,Oncology ,Child, Preschool ,Relative risk ,Cohort ,Female ,Self Report ,business ,Follow-Up Studies ,Cohort study - Abstract
Previous studies have shown decreased pregnancy rates and early menopause in female cancer survivors; however, infertility rates and reproductive interventions have not been studied. We investigated infertility and time to pregnancy in female childhood cancer survivors, and analysed treatment characteristics associated with infertility and subsequent pregnancy.The Childhood Cancer Survivor Study (CCSS) is a cohort study including 5 year cancer survivors from 26 Canadian and US institutions who were younger than 21 years at the time of diagnosis between Jan 1, 1970, and Dec 31, 1986, and a sibling control group. We included women aged 18-39 years who had ever been sexually active. We gathered demographic, medical, and reproductive data via a baseline questionnaire, and quantified exposure to alkylating agents and radiation therapy. Self-reported infertility, medical treatment for infertility, time to first pregnancy in survivors and siblings, and the risk of infertility in survivors by demographic, disease, and treatment variables were analysed.3531 survivors and 1366 female sibling controls who enrolled between Nov 3, 1992, and April 4, 2004, were included. Compared with their siblings, survivors had an increased risk (relative risk [RR] 1·48 [95% CI 1·23-1·78]; p0·0001) of clinical infertility (ie,1 year of attempts at conception without success), which was most pronounced at early reproductive ages (RR 2·92 [95% CI 1·18-7·20], p=0·020, in participants ≤24 years; 1·61 [1·05-2·48], p=0·029, in those aged 25-29 years; and 1·37 [1·11-1·69], p=0·0035, in those aged 30-40 years). Despite being equally likely to seek treatment for infertility, survivors were less likely than were their siblings to be prescribed drugs for treatment of infertility (0·57 [95% CI 0·46-0·70], p0·0001). Increasing doses of uterine radiation and alkylating agent chemotherapy were strongly associated with infertility. Although survivors had an increased time to pregnancy compared with their siblings (p=0·032), 292 (64%) of 455 participants with self-reported clinical infertility achieved a pregnancy.A more comprehensive understanding of infertility after cancer is crucial for counselling and decision making about future conception attempts and fertility preservation.National Cancer Institute, American Lebanese Syrian Associated Charities, Swim Across America.
- Published
- 2013
29. Radiation Dose to the Esophagus From Breast Cancer Radiation Therapy, 1943-1996: An International Population-Based Study of 414 Patients
- Author
-
Berthe M.P. Aleman, Lindsay M. Morton, Marilyn Stovall, Steven L. Simon, Deukwoo Kwon, Lois B. Travis, Rochelle E. Curtis, Rita E. Weathers, Stephanie Lamart, Rebecca M. Howell, and Susan A. Smith
- Subjects
Organs at Risk ,Cancer Research ,Neoplasms, Radiation-Induced ,Esophageal Neoplasms ,medicine.medical_treatment ,Breast Neoplasms ,Mastectomy, Segmental ,Risk Assessment ,Article ,Esophagus ,Breast cancer ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Thoracic Wall ,Mastectomy ,Lymphatic Irradiation ,Radiation ,Phantoms, Imaging ,business.industry ,Radiation dose ,Uncertainty ,Dose-Response Relationship, Radiation ,Neoplasms, Second Primary ,Radiotherapy Dosage ,Esophageal cancer ,medicine.disease ,Europe ,Radiation therapy ,medicine.anatomical_structure ,Lymphatic system ,Oncology ,North America ,Female ,Lymph ,Nuclear medicine ,business - Abstract
Purpose To provide dosimetric data for an epidemiologic study on the risk of second primary esophageal cancer among breast cancer survivors, by reconstructing the radiation dose incidentally delivered to the esophagus of 414 women treated with radiation therapy for breast cancer during 1943-1996 in North America and Europe. Methods and Materials We abstracted the radiation therapy treatment parameters from each patient's radiation therapy record. Treatment fields included direct chest wall (37% of patients), medial and lateral tangentials (45%), supraclavicular (SCV, 64%), internal mammary (IM, 44%), SCV and IM together (16%), axillary (52%), and breast/chest wall boosts (7%). The beam types used were 60 Co (45% of fields), orthovoltage (33%), megavoltage photons (11%), and electrons (10%). The population median prescribed dose to the target volume ranged from 21 Gy to 40 Gy. We reconstructed the doses over the length of the esophagus using abstracted patient data, water phantom measurements, and a computational model of the human body. Results Fields that treated the SCV and/or IM lymph nodes were used for 85% of the patients and delivered the highest doses within 3 regions of the esophagus: cervical (population median 38 Gy), upper thoracic (32 Gy), and middle thoracic (25 Gy). Other fields (direct chest wall, tangential, and axillary) contributed substantially lower doses (approximately 2 Gy). The cervical to middle thoracic esophagus received the highest dose because of its close proximity to the SCV and IM fields and less overlying tissue in that part of the chest. The location of the SCV field border relative to the midline was one of the most important determinants of the dose to the esophagus. Conclusions Breast cancer patients in this study received relatively high incidental radiation therapy doses to the esophagus when the SCV and/or IM lymph nodes were treated, whereas direct chest wall, tangentials, and axillary fields contributed lower doses.
- Published
- 2013
30. Risk of Salivary Gland Cancer After Childhood Cancer: A Report From the Childhood Cancer Survivor Study
- Author
-
Kayla Stratton, Peter D. Inskip, Rita E. Weathers, Marilyn Stovall, Sue Hammond, Sarah S. Donaldson, Gregory T. Armstrong, Leslie L. Robison, Joseph P. Neglia, Houda Boukheris, Susan A. Smith, Ann C. Mertens, and Ethel S. Gilbert
- Subjects
Male ,Risk ,Oncology ,Cancer Research ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,Adolescent ,Alcohol Drinking ,medicine.medical_treatment ,Population ,Antineoplastic Agents ,Childhood Cancer Survivor Study ,Salivary Glands ,Article ,Young Adult ,Neoplasms ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Cumulative incidence ,Poisson Distribution ,Survivors ,Child ,education ,Retrospective Studies ,education.field_of_study ,Radiation ,business.industry ,Incidence ,Incidence (epidemiology) ,Smoking ,Age Factors ,Infant ,Cancer ,Neoplasms, Second Primary ,Radiotherapy Dosage ,Salivary Gland Neoplasms ,medicine.disease ,Surgery ,Radiation therapy ,Salivary gland cancer ,Child, Preschool ,Relative risk ,Female ,business ,SEER Program - Abstract
Purpose To evaluate effects of radiation therapy, chemotherapy, cigarette smoking, and alcohol consumption on the risk of second primary salivary gland cancer (SGC) in the Childhood Cancer Survivor Study (CCSS). Methods and Materials Standardized incidence ratios (SIR) and excess absolute risks (EAR) of SGC in the CCSS were calculated using incidence rates from Surveillance, Epidemiology, and End Results population-based cancer registries. Radiation dose to the salivary glands was estimated based on medical records. Poisson regression was used to assess risks with respect to radiation dose, chemotherapy, smoking, and alcohol consumption. Results During the time period of the study, 23 cases of SGC were diagnosed among 14,135 childhood cancer survivors. The mean age at diagnosis of the first primary cancer was 8.3 years, and the mean age at SGC diagnosis was 24.8 years. The incidence of SGC was 39-fold higher in the cohort than in the general population (SIR = 39.4; 95% CI = 25.4-57.8). The EAR was 9.8 per 100,000 person-years. Risk increased linearly with radiation dose (excess relative risk = 0.36/Gy; 95% CI = 0.06-2.5) and remained elevated after 20 years. There was no significant trend of increasing risk with increasing dose of chemotherapeutic agents, pack-years of cigarette smoking, or alcohol intake. Conclusion Although the cumulative incidence of SGC was low, childhood cancer survivors treated with radiation experienced significantly increased risk for at least 2 decades after exposure, and risk was positively associated with radiation dose. Results underscore the importance of long-term follow up of childhood cancer survivors for the development of new malignancies.
- Published
- 2013
31. Absolute Risk Prediction of Second Primary Thyroid Cancer Among 5-Year Survivors of Childhood Cancer
- Author
-
Sarah S. Donaldson, Marilyn Stovall, Ann C. Mertens, Alice J. Sigurdson, Cécile M. Ronckers, Leslie L. Robison, Parveen Bhatti, Susan A. Smith, Rita E. Weathers, Charles A. Sklar, Ruth M. Pfeiffer, Margaret A. Tucker, Wendy M. Leisenring, Stephanie Kovalchik, Harald Anderson, Sue Hammond, Lene H.S. Veiga, Peter D. Inskip, and Florent de Vathaire
- Subjects
Adult ,Male ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Adolescent ,Childhood Cancer Survivor Study ,Risk Assessment ,Young Adult ,Neoplasms ,Original Reports ,medicine ,Humans ,Survivors ,Thyroid Neoplasms ,Risk factor ,Child ,Thyroid cancer ,Models, Statistical ,business.industry ,Absolute risk reduction ,Cancer ,Neoplasms, Second Primary ,Middle Aged ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Survival Rate ,Oncology ,Case-Control Studies ,Child, Preschool ,Relative risk ,Cohort ,Female ,Risk assessment ,business ,Follow-Up Studies - Abstract
Purpose We developed three absolute risk models for second primary thyroid cancer to assist with long-term clinical monitoring of childhood cancer survivors. Patients and Methods We used data from the Childhood Cancer Survivor Study (CCSS) and two nested case-control studies (Nordic CCSS; Late Effects Study Group). Model M1 included self-reported risk factors, model M2 added basic radiation and chemotherapy treatment information abstracted from medical records, and model M3 refined M2 by incorporating reconstructed radiation absorbed dose to the thyroid. All models were validated in an independent cohort of French childhood cancer survivors. Results M1 included birth year, initial cancer type, age at diagnosis, sex, and past thyroid nodule diagnosis. M2 added radiation (yes/no), radiation to the neck (yes/no), and alkylating agent (yes/no). Past thyroid nodule was consistently the strongest risk factor (M1 relative risk [RR], 10.8; M2 RR, 6.8; M3 RR, 8.2). In the validation cohort, 20-year absolute risk predictions for second primary thyroid cancer ranged from 0.04% to 7.4% for M2. Expected events agreed well with observed events for each model, indicating good calibration. All models had good discriminatory ability (M1 area under the receiver operating characteristics curve [AUC], 0.71; 95% CI, 0.64 to 0.77; M2 AUC, 0.80; 95% CI, 0.73 to 0.86; M3 AUC, 0.75; 95% CI, 0.69 to 0.82). Conclusion We developed and validated three absolute risk models for second primary thyroid cancer. Model M2, with basic prior treatment information, could be useful for monitoring thyroid cancer risk in childhood cancer survivors.
- Published
- 2013
32. Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
- Author
-
Kevin C. Oeffinger, Lillian R. Meacham, Daniel M. Green, Leslie L. Robison, Marilyn Stovall, Gregory T. Armstrong, Kristy Seidel, Charles A. Sklar, Rita E. Weathers, Sogol Mostoufi-Moab, Wendy M. Leisenring, and Jill P. Ginsberg
- Subjects
Adult ,Male ,Canada ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Adolescent ,030209 endocrinology & metabolism ,Hypopituitarism ,Childhood Cancer Survivor Study ,Endocrine System Diseases ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cancer Survivors ,Neoplasms ,medicine ,Endocrine system ,Humans ,Cumulative incidence ,Survivors ,Young adult ,Child ,Retrospective Studies ,business.industry ,Age Factors ,Primary hypothyroidism ,Retrospective cohort study ,ORIGINAL REPORTS ,Middle Aged ,medicine.disease ,United States ,Oncology ,Child, Preschool ,030220 oncology & carcinogenesis ,Disease Progression ,Female ,business ,Cohort study - Abstract
Purpose The development of endocrinopathies in survivors of childhood cancer as they age remains understudied. We characterized endocrine outcomes in aging survivors from the Childhood Cancer Survivor Study on the basis of therapeutic exposures. Patients and Methods We analyzed self-reported conditions in 14,290 5-year survivors from the Childhood Cancer Survivor Study, with a median age 6 years (range, < 1 to 20 years) at diagnosis and 32 years (range, 5 to 58 years) at last follow-up. Identification of high-risk therapeutic exposures was adopted from the Children’s Oncology Group Long-Term Follow-Up Guidelines. Cumulative incidence curves and prevalence estimates quantified and regression models compared risks of primary hypothyroidism, hyperthyroidism, thyroid neoplasms, hypopituitarism, obesity, diabetes mellitus, or gonadal dysfunction between survivors and siblings. Results The cumulative incidence and prevalence of endocrine abnormalities increased across the lifespan of survivors (P < .01 for all). Risk was significantly higher in survivors exposed to high-risk therapies compared with survivors not so exposed for primary hypothyroidism (hazard ratio [HR], 6.6; 95% CI, 5.6 to 7.8), hyperthyroidism (HR, 1.8; 95% CI, 1.2 to 2.8), thyroid nodules (HR, 6.3; 95% CI, 5.2 to 7.5), thyroid cancer (HR, 9.2; 95% CI, 6.2 to 13.7), growth hormone deficiency (HR, 5.3; 95% CI, 4.3 to 6.4), obesity (relative risk, 1.8; 95% CI, 1.7 to 2.0), and diabetes mellitus (relative risk, 1.9; 95% CI, 1.6 to 2.4). Women exposed to high-risk therapies had six-fold increased risk for premature ovarian insufficiency (P < .001), and men demonstrated higher prevalence of testosterone replacement (P < .001) after cyclophosphamide equivalent dose of 20 g/m2 or greater or testicular irradiation with 20 Gy or greater. Survivors demonstrated an increased risk for all thyroid disorders and diabetes mellitus regardless of treatment exposures compared with siblings (P < .001 for all). Conclusion Endocrinopathies in survivors increased substantially over time, underscoring the need for lifelong subspecialty follow-up of those at risk.
- Published
- 2016
33. Skin dose during radiotherapy: a summary and general estimation technique
- Author
-
Marilyn Stovall, Stephen F Kry, Rita E. Weathers, and Susan A. Smith
- Subjects
Adult ,medicine.medical_treatment ,Monte Carlo method ,Treatment parameters ,Radiation Dosage ,Imaging phantom ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,skin dose ,basal cell carcinoma ,medicine ,Humans ,Radiation Oncology Physics ,Dosimetry ,Radiology, Nuclear Medicine and imaging ,Child ,Instrumentation ,radiotherapy ,Skin ,Radiation ,skin cancer ,integumentary system ,Phantoms, Imaging ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Radiotherapy Dosage ,medicine.disease ,Skin dose ,3. Good health ,Radiation therapy ,030220 oncology & carcinogenesis ,Thermoluminescent dosimeter ,Skin cancer ,business ,Nuclear medicine ,Monte Carlo Method ,surface dose - Abstract
The skin dose associated with radiotherapy may be of interest for clinical evaluation or investigating the risk of late effects. However, skin dose is not intuitive and is difficult to measure. Our objectives were to develop and evaluate a general estimation technique for skin dose based on treatment parameters. The literature on skin dose was supplemented with measurements and Monte Carlo simulations. Using all available data, a general dosimetry system was developed (in the form of a series of equations) to estimate skin dose based on treatment parameters including field size, the presence of a block tray, and obliquity of the treatment field. For out‐of‐field locations, the distance from the field edge was also considered. This dosimetry system was then compared to TLD measurements made on the surface of a phantom. As compared to measurements, the general dosimetry system was able to predict skin dose within, on average, 21% of the local dose (4% of the Dmax dose). Skin dose for patients receiving radiotherapy can be estimated with reasonable accuracy using a set of general rules and equations. PACS numbers: 87.53.‐j, 87.53.Bn, 87.55.ne
- Published
- 2012
34. Congenital Anomalies in the Children of Cancer Survivors: A Report From the Childhood Cancer Survivor Study
- Author
-
John J. Mulvihill, John Whitton, Rita E. Weathers, Lisa B. Signorello, Marilyn Stovall, John D. Boice, Daniel M. Green, Ann C. Mertens, Leslie L. Robison, and Heather M. Munro
- Subjects
Adult ,Male ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Offspring ,medicine.medical_treatment ,Childhood Cancer Survivor Study ,Congenital Abnormalities ,Cohort Studies ,Young Adult ,Risk Factors ,Neoplasms ,medicine ,Humans ,Survivors ,Young adult ,Child ,Retrospective Studies ,business.industry ,Infant ,Cancer ,Retrospective cohort study ,ORIGINAL REPORTS ,Odds ratio ,medicine.disease ,Radiation therapy ,Oncology ,Child, Preschool ,Female ,business ,Cohort study - Abstract
Purpose Children with cancer receive mutagenic treatments, which raises concern about the potential transmissibility of germline damage to their offspring. This question has been inadequately studied to date because of a lack of detailed individual treatment exposure assessment such as gonadal radiation doses. Methods Within the Childhood Cancer Survivor Study, we performed a retrospective cohort analysis of validated cases of congenital anomalies among 4,699 children of 1,128 male and 1,627 female childhood cancer survivors. We quantified chemotherapy with alkylating agents and radiotherapy doses to the testes and ovaries and related these exposures to risk of congenital anomalies using logistic regression. Results One hundred twenty-nine children had at least one anomaly (prevalence = 2.7%). For children whose mothers were exposed to radiation or alkylating agents versus neither, the prevalence of anomalies was 3.0% versus 3.5% (P = .51); corresponding figures were 1.9% versus 1.7% (P = .79) for the children of male survivors. Neither ovarian radiation dose (mean, 1.19 Gy; odds ratio [OR] = 0.59; 95% CI, 0.20 to 1.75 for 2.50+ Gy) nor testicular radiation dose (mean, 0.48 Gy; OR = 1.01; 95% CI, 0.36 to 2.83 for 0.50+ Gy) was related to risk of congenital anomalies. Treatment with alkylating agents also was not significantly associated with anomalies in the children of male or female survivors. Conclusion Our findings offer strong evidence that the children of cancer survivors are not at significantly increased risk for congenital anomalies stemming from their parent's exposure to mutagenic cancer treatments. This information is important for counseling cancer survivors planning to have children.
- Published
- 2012
35. Chemotherapy and Thyroid Cancer Risk: A Report from the Childhood Cancer Survivor Study
- Author
-
Ann C. Mertens, Marilyn Stovall, Anna T. Meadows, Sarah S. Donaldson, Charles A. Sklar, Peter D. Inskip, Rita E. Weathers, Alice J. Sigurdson, Wendy M. Leisenring, Lene H.S. Veiga, Debra L. Friedman, Joseph P. Neglia, Cécile M. Ronckers, Leslie L. Robison, Susan A. Smith, Parveen Bhatti, and Sue Hammond
- Subjects
Adult ,Oncology ,Canada ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,Adolescent ,Epidemiology ,medicine.medical_treatment ,Antineoplastic Agents ,Childhood Cancer Survivor Study ,Article ,Cohort Studies ,Young Adult ,Risk Factors ,Internal medicine ,medicine ,Humans ,Cumulative incidence ,Survivors ,Thyroid Neoplasms ,Child ,Thyroid cancer ,Radiotherapy ,business.industry ,Thyroid ,Infant, Newborn ,Infant ,Cancer ,Dose-Response Relationship, Radiation ,Middle Aged ,medicine.disease ,United States ,Surgery ,Radiation therapy ,Cell killing ,medicine.anatomical_structure ,Child, Preschool ,Relative risk ,business - Abstract
Background: Although ionizing radiation is an established environmental risk factor for thyroid cancer, the effect of chemotherapy drugs on thyroid cancer risk remains unclear. We evaluated the chemotherapy-related risk of thyroid cancer in childhood cancer survivors and the possible joint effects of chemotherapy and radiotherapy. Methods: The study included 12,547 five-year survivors of childhood cancer diagnosed during 1970 through 1986. Chemotherapy and radiotherapy information was obtained from medical records, and radiation dose was estimated to the thyroid gland. Cumulative incidence and relative risks were calculated with life-table methods and Poisson regression. Chemotherapy-related risks were evaluated separately by categories of radiation dose. Results: Histologically confirmed thyroid cancer occurred in 119 patients. Thirty years after the first childhood cancer treatment, the cumulative incidence of thyroid cancer was 1.3% (95% CI, 1.0–1.6) for females and 0.6% (0.4–0.8) for males. Among patients with thyroid radiation doses of 20 Gy or less, treatment with alkylating agents was associated with a significant 2.4-fold increased risk of thyroid cancer (95% CI, 1.3–4.5; P = 0.002). Chemotherapy risks decreased as radiation dose increased, with a significant decrease for patients treated with alkylating agents (Ptrend = 0.03). No chemotherapy-related risk was evident for thyroid radiation doses more than 20 Gy. Conclusions: Treatments with alkylating agents increased thyroid cancer risk, but only in the radiation dose range less than 20 Gy, in which cell sparing likely predominates over cell killing. Impact: Our study adds to the evidence for chemotherapy agent–specific increased risks of thyroid cancer, which to date, were mainly thought to be related to prior radiotherapy. Cancer Epidemiol Biomarkers Prev; 21(1); 92–101. ©2011 AACR.
- Published
- 2012
36. Twenty-five year follow-up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study
- Author
-
Rita E. Weathers, Yutaka Yasui, Daniel M. Green, Amanda M. Termuhlen, Jean M. Tersak, Leslie L. Robison, Charles A. Sklar, Qi Liu, Melvin Deutsch, Greg Armstrong, Marilyn Stovall, and Kevin C. Oeffinger
- Subjects
education.field_of_study ,Pediatrics ,medicine.medical_specialty ,business.industry ,Population ,Hazard ratio ,Retrospective cohort study ,Hematology ,Childhood Cancer Survivor Study ,Standardized mortality ratio ,Oncology ,Pediatrics, Perinatology and Child Health ,Cohort ,Medicine ,Cumulative incidence ,education ,business ,Cohort study - Abstract
Background Treatment cures over 90% of children with Wilms tumor (WT) who subsequently risk late morbidity and mortality. This study describes the 25-year outcomes of 5-year WT survivors in the Childhood Cancer Survivor Study (CCSS). Procedure The CCSS, a multi-institutional retrospective cohort study, assessed WT survivors (N = 1,256), diagnosed 1970–1986, for chronic health conditions, health status, health care utilization, socioeconomic status, subsequent malignant neoplasms (SMNs), and mortality compared to the US population and a sibling cohort (N = 4,023). Results The cumulative incidence of all and severe chronic health conditions was 65.4% and 24.2% at 25 years. Hazard ratios (HR) were 2.0, 95% confidence interval (CI) 1.8–2.3 for grades 1–4 and 4.7, 95%CI 3.6–6.1 for grades 3 and 4, compared to sibling group. WT survivors reported more adverse general health status than the sibling group (prevalence ratio [PR] 1.7; 95%CI 1.2–2.4), but mental health status, socioeconomic outcome, and health care utilization were similar. The cumulative incidence of SMN was 3.0% (95%CI 1.9–4.0%) and of mortality was 6.1% (95%CI 4.7–7.4%). Radiation exposure increased the likelihood of congestive heart failure (CHF) (no doxorubicin—HR 6.6; 95%CI 1.6–28.3; doxorubicin ≤250 mg/m2—HR 13.0; 95%CI 1.9–89.7; doxorubicin >250 mg/m2—HR 18.3; 95%CI 3.8–88.2), SMN (standardized incidence ratio [SIR] 9.0; 95%CI 3.9–17.7 with and 4.9; 95%CI 1.8–10.6 without doxorubicin) and death. Conclusion Long-term survivors of WT treated from 1970 to 1986 are at increased risk of treatment related morbidity and mortality 25 years from diagnosis. Pediatr Blood Cancer 2011; 57: 1210–1216. © 2011 Wiley Periodicals, Inc.
- Published
- 2011
37. Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study
- Author
-
Ann C. Mertens, Heather M. Munro, Daniel M. Green, Leslie L. Robison, Lisa B. Signorello, John J. Mulvihill, John Whitton, Rita E. Weathers, Marilyn Stovall, and John D. Boice
- Subjects
Male ,medicine.medical_specialty ,Offspring ,Pregnancy ,Uterine cancer ,Neoplasms ,Infant Mortality ,Testis ,medicine ,Humans ,Survivors ,Testicular cancer ,Gynecology ,business.industry ,Ovary ,Uterus ,Infant, Newborn ,Cancer ,Radiotherapy Dosage ,Retrospective cohort study ,General Medicine ,Stillbirth ,medicine.disease ,Maternal Exposure ,Fertilization ,Relative risk ,Female ,business ,Cohort study - Abstract
Summary Background The reproductive implications of mutagenic treatments given to children with cancer are not clear. By studying the risk of untoward pregnancy outcomes, we indirectly assessed the risk of transmission of germline damage to the offspring of survivors of childhood cancer who were given radiotherapy and chemotherapy. Methods We did a retrospective cohort analysis, within the Childhood Cancer Survivor Study (CCSS), of the risk of stillbirth and neonatal death among the offspring of men and women who had survived childhood cancer. Patients in CCSS were younger than 21 years at initial diagnosis of an eligible cancer, were treated at 25 US institutions and one Canadian institution, and had survived for at least 5 years after diagnosis. We quantified the chemotherapy given to patients, and the preconception radiation doses to the testes, ovaries, uterus, and pituitary gland, and related these to the risk of stillbirth or neonatal death using Poisson regression analysis. Findings Among 1148 men and 1657 women who had survived childhood cancer, there were 4946 pregnancies. Irradiation of the testes (16 [1%] of 1270; adjusted relative risk 0·8 [95% CI 0·4–1·6]; mean dose 0·53 Gy [SD 1·40]) and pituitary gland (17 [3%] of 510, 1·1 [0·5–2·4] for more than 20·00 Gy; mean dose 10·20 Gy [13·0] for women), and chemotherapy with alkylating drugs (26 [2%] of 1195 women, 0·9 [0·5–1·5]; ten [1%] of 732 men, 1·2 [0·5–2·5]) were not associated with an increased risk of stillbirth or neonatal death. Uterine and ovarian irradiation significantly increased risk of stillbirth and neonatal death at doses greater than 10·00 Gy (five [18%] of 28, 9·1 [3·4–24·6]). For girls treated before menarche, irradiation of the uterus and ovaries at doses as low as 1·00–2·49 Gy significantly increased the risk of stillbirth or neonatal death (three [4%] of 69, 4·7 [1·2–19·0]). Interpretation Our findings do not support concern about heritable genetic changes affecting the risk of stillbirth and neonatal death in the offspring of men exposed to gonadal irradiation. However, uterine and ovarian irradiation had serious adverse effects on the offspring that were probably related to uterine damage. Careful management is warranted of pregnancies in women given high doses of pelvic irradiation before puberty. Funding Westlakes Research Institute, National Cancer Institute, and Children's Cancer Research Fund.
- Published
- 2010
38. Radiation dose and volume to the pancreas and subsequent risk of diabetes mellitus: A report from the Childhood Cancer Survivor study
- Author
-
Charles A. Sklar, Rita E. Weathers, Eric J. Chow, Gregory T. Armstrong, Patrick Hilden, Wendy M. Leisenring, Sogol Mostoufi-Moab, Rebecca M. Howell, Lillian R. Meacham, Chaya S. Moskowitz, Danielle Novetsky Friedman, Emily S. Tonorezos, Leslie L. Robison, Suzanne L. Wolden, Susan A. Smith, Kevin C. Oeffinger, and John Whitton
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Childhood cancer ,Radiation dose ,Childhood Cancer Survivor Study ,medicine.disease ,medicine.anatomical_structure ,Increased risk ,Diabetes mellitus ,Internal medicine ,Medicine ,Abdominal radiotherapy ,business ,Pancreas - Abstract
10564Background: Childhood cancer survivors exposed to abdominal radiotherapy (abdRT) are at increased risk for diabetes mellitus (DM). We examined the association between DM risk and pancreatic ra...
- Published
- 2018
39. Hypothyroidism after Radiation Therapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study
- Author
-
Jay H. Lubin, Alice J. Sigurdson, Leslie L. Robison, Gregory T. Armstrong, Susan A. Smith, Rita E. Weathers, Alina V. Brenner, Peter D. Inskip, Evgenia Ostroumova, Charles A. Sklar, Wendy M. Leisenring, Eric J. Chow, Marilyn Stovall, and Lene H.S. Veiga
- Subjects
Adult ,Male ,Hypothalamo-Hypophyseal System ,endocrine system ,Pediatrics ,medicine.medical_specialty ,Adolescent ,endocrine system diseases ,medicine.medical_treatment ,Thyroid Gland ,Biophysics ,030209 endocrinology & metabolism ,Childhood Cancer Survivor Study ,Article ,Young Adult ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Cancer Survivors ,Hypothyroidism ,Risk Factors ,Neoplasms ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Poisson regression ,Young adult ,Child ,Radiation Injuries ,Thyroid cancer ,Radiation ,business.industry ,Thyroid ,Infant, Newborn ,Infant ,Dose-Response Relationship, Radiation ,Odds ratio ,Middle Aged ,medicine.disease ,Radiation therapy ,medicine.anatomical_structure ,Child, Preschool ,030220 oncology & carcinogenesis ,Cohort ,symbols ,Female ,business - Abstract
While thyroid cancer risks from exposure to ionizing radiation early in life are well characterized quantitatively, the association of radiation with nonmalignant, functional thyroid disorders has been less studied. Here, we report on a risk analysis study of hypothyroidism with radiation dose to the thyroid gland and the hypothalamic-pituitary axis among survivors of childhood cancer. Utilizing data from the Childhood Cancer Survivor Study, a cohort of 14,364 five-year survivors of childhood cancer diagnosed at 26 hospitals in the U.S. and Canada between 1970 and 1986 and followed through 2009, the occurrence of hypothyroidism was ascertained among 12,015 survivors through serial questionnaires. Radiation doses to the thyroid gland and pituitary gland were estimated from radiotherapy records. Binary outcome regression was used to estimate prevalence odds ratios for hypothyroidism at five years from diagnosis of childhood cancer and Poisson regression to model incidence rate ratios (RR) after the first five years. A total of 1,193 cases of hypothyroidism were observed, 777 (65%) of which occurred five or more years after cancer diagnosis. The cumulative proportion affected with hypothyroidism (prevalence at five years after cancer diagnosis plus incidence through 30 years after cancer diagnosis) was highest among five-year survivors of Hodgkin lymphoma (32.3%; 95% CI: 29.5-34.9) and cancers of the central nervous system (17.7%; 95% CI: 15.2-20.4). The incidence rate was significantly associated with radiation dose to the thyroid and pituitary. The joint association of hypothyroidism with thyroid and pituitary dose was sub-additive for pituitary doses greater than 16 Gy. In particular, a very strong thyroid radiation dose dependence at low-to-moderate pituitary/hypothalamic doses was diminished at high pituitary doses. Radiation-related risks were higher in males than females and inversely associated with age at exposure and time since exposure but remained elevated more than 25 years after exposure. Our findings indicated that hypothyroidism was significantly associated with treatment with bleomycin (RR = 3.4; 95% CI: 1.6-7.3) and the alkylating agents cyclohexyl-chloroethyl-nitrosourea (CCNU) (RR = 3.0; 95% CI: 1.5-5.3) and cyclophosphamide (RR = 1.3; 95% CI: 1.0-1.8), with a significant dose response for CCNU ( P0.01). The risk of hypothyroidism among childhood cancer survivors treated with radiation depends both on direct, dose-dependent radiation-induced damage to the thyroid gland and on dose-dependent indirect effects secondary to irradiation of the hypothalamic-pituitary axis. The dose-response relationship for each site depends on dose to the other. Radiation-related risk persists for more than 25 years after treatment. Treatment with certain chemotherapy agents may increase the risk of hypothyroidism.
- Published
- 2018
40. Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer
- Author
-
Lillian R. Meacham, Gregory T. Armstrong, Irma W. E. M. van Dijk, Melissa M. Hudson, Kevin C. Oeffinger, Marilyn Stovall, Yutaka Yasui, Flora E. van Leeuwen, Helena J H van der Pal, Cécile M. Ronckers, Leslie L. Robison, Yan Chen, Charles A. Sklar, Daniel A. Mulrooney, Daniel M. Green, Elizabeth A M Feijen, Kirsten K. Ness, Leontien C. M. Kremer, William L. Border, Eric J. Chow, Rita E. Weathers, CCA - Cancer Treatment and quality of life, APH - Quality of Care, Other departments, CCA - Cancer Treatment and Quality of Life, ARD - Amsterdam Reproduction and Development, Paediatric Oncology, and Radiotherapy
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Concordance ,Myocardial Ischemia ,Disease ,Childhood Cancer Survivor Study ,030204 cardiovascular system & hematology ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Internal medicine ,medicine ,Humans ,Cumulative incidence ,Survivors ,Young adult ,Child ,Stroke ,business.industry ,Incidence ,Infant ,ORIGINAL REPORTS ,Middle Aged ,medicine.disease ,Oncology ,Child, Preschool ,030220 oncology & carcinogenesis ,North America ,Cohort ,Physical therapy ,Female ,business ,Cohort study - Abstract
Purpose We aimed to predict individual risk of ischemic heart disease and stroke in 5-year survivors of childhood cancer. Patients and Methods Participants in the Childhood Cancer Survivor Study (CCSS; n = 13,060) were observed through age 50 years for the development of ischemic heart disease and stroke. Siblings (n = 4,023) established the baseline population risk. Piecewise exponential models with backward selection estimated the relationships between potential predictors and each outcome. The St Jude Lifetime Cohort Study (n = 1,842) and the Emma Children’s Hospital cohort (n = 1,362) were used to validate the CCSS models. Results Ischemic heart disease and stroke occurred in 265 and 295 CCSS participants, respectively. Risk scores based on a standard prediction model that included sex, chemotherapy, and radiotherapy (cranial, neck, and chest) exposures achieved an area under the curve and concordance statistic of 0.70 and 0.70 for ischemic heart disease and 0.63 and 0.66 for stroke, respectively. Validation cohort area under the curve and concordance statistics ranged from 0.66 to 0.67 for ischemic heart disease and 0.68 to 0.72 for stroke. Risk scores were collapsed to form statistically distinct low-, moderate-, and high-risk groups. The cumulative incidences at age 50 years among CCSS low-risk groups were < 5%, compared with approximately 20% for high-risk groups ( P < .001); cumulative incidence was only 1% for siblings ( P < .001 v low-risk survivors). Conclusion Information available to clinicians soon after completion of childhood cancer therapy can predict individual risk for subsequent ischemic heart disease and stroke with reasonable accuracy and discrimination through age 50 years. These models provide a framework on which to base future screening strategies and interventions.
- Published
- 2018
41. Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays
- Author
-
Paul G Meltzer, Joseph P. Neglia, Xiaohong R. Yang, Marilyn Stovall, Yonghong Wang, Hunter Bennett, Sue Hammond, Kiyohiko Mabuchi, Rita E. Weathers, Smita Bhatia, Laura S. Burke, Sean Davis, Peter D. Inskip, J. Keith Killian, Louise C. Strong, and Leslie L. Robison
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,DNA Copy Number Variations ,Receptor, ErbB-2 ,medicine.medical_treatment ,Estrogen receptor ,lcsh:Medicine ,Breast Neoplasms ,Childhood Cancer Survivor Study ,Biology ,Young Adult ,Breast cancer ,Internal medicine ,Gene duplication ,medicine ,Humans ,Risk factor ,Young adult ,skin and connective tissue diseases ,lcsh:Science ,Comparative Genomic Hybridization ,Multidisciplinary ,lcsh:R ,Gene Amplification ,Neoplasms, Second Primary ,Middle Aged ,medicine.disease ,3. Good health ,Radiation therapy ,Adult Survivors of Child Adverse Events ,Female ,lcsh:Q ,Comparative genomic hybridization ,Chromosomes, Human, Pair 17 ,Research Article - Abstract
Ionizing radiation is an established risk factor for breast cancer. Epidemiologic studies of radiation-exposed cohorts have been primarily descriptive; molecular events responsible for the development of radiation-associated breast cancer have not been elucidated. In this study, we used array comparative genomic hybridization (array-CGH) to characterize genome-wide copy number changes in breast tumors collected in the Childhood Cancer Survivor Study (CCSS). Array-CGH data were obtained from 32 cases who developed a second primary breast cancer following chest irradiation at early ages for the treatment of their first cancers, mostly Hodgkin lymphoma. The majority of these cases developed breast cancer before age 45 (91%, n = 29), had invasive ductal tumors (81%, n = 26), estrogen receptor (ER)-positive staining (68%, n = 19 out of 28), and high proliferation as indicated by high Ki-67 staining (77%, n = 17 out of 22). Genomic regions with low-copy number gains and losses and high-level amplifications were similar to what has been reported in sporadic breast tumors, however, the frequency of amplifications of the 17q12 region containing human epidermal growth factor receptor 2 (HER2) was much higher among CCSS cases (38%, n = 12). Our findings suggest that second primary breast cancers in CCSS were enriched for an “amplifier” genomic subgroup with highly proliferative breast tumors. Future investigation in a larger irradiated cohort will be needed to confirm our findings.
- Published
- 2015
42. Female Survivors of Childhood Cancer: Preterm Birth and Low Birth Weight Among Their Children
- Author
-
Catherine E. Kasper, Leslie L. Robison, Lisa B. Signorello, Marilyn Stovall, Sarah S. Donaldson, Rita E. Weathers, John Whitton, John D. Boice, Sarah S. Cohen, Daniel M. Green, Cristina Bosetti, and Ann C. Mertens
- Subjects
Adult ,Male ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Antineoplastic Agents ,Childhood Cancer Survivor Study ,Risk Assessment ,Wilms Tumor ,Article ,Pregnancy ,Risk Factors ,Neoplasms ,Surveys and Questionnaires ,Odds Ratio ,medicine ,Humans ,Registries ,Survivors ,Risk factor ,Child ,Menarche ,Fetal Growth Retardation ,Radiotherapy ,business.industry ,Age Factors ,Infant, Newborn ,Cancer ,Confounding Factors, Epidemiologic ,Wilms' tumor ,Genitalia, Female ,Infant, Low Birth Weight ,medicine.disease ,Kidney Neoplasms ,humanities ,Pregnancy Complications ,Low birth weight ,Logistic Models ,Oncology ,Premature birth ,Infant, Small for Gestational Age ,Premature Birth ,Population study ,Female ,medicine.symptom ,business - Abstract
As progress in improving the survival of childhood cancer patients is achieved, there is a concomitant concern about long-term health effects among survivors, particularly effects among those exposed to intensive radiotherapy and chemotherapy. Concerns have emerged, for example, about the effects of these therapies on the reproductive capacity of the survivors, including implications for fertility, pregnancy outcomes, and health problems in the offspring (1-3). Some patients who are exposed to high-dose chemotherapy or gonadal irradiation experience permanent infertility (depending on the dosages and their age when treated) (4), but many survivors retain reproductive function and wish to have children (5). With regard to pregnancy outcomes, some studies have documented an increased risk of fetal death (either spontaneous abortion or perinatal death) for female survivors of childhood cancer (6-10). These findings were primarily reported among Wilms tumor survivors or were related to treatment involving high-dose abdominal irradiation (6-9). However, in a recent analysis of a much larger study population of childhood cancer survivors than in previous studies (11,12), we found little convincing evidence that rates of fetal loss were elevated for female survivors of childhood cancer or for the partners of male survivors of childhood cancer. Previous investigators have also noted an increased risk of preterm birth and/or low birth weight for the offspring of female survivors of Wilms tumor who received irradiation to the flank, pelvis, or abdomen (6,8,9,13,14). An additional recent study found an excess of low birth weight among the children of women who received direct abdominal—pelvic irradiation, irrespective of cancer type (7). Information on the risk of preterm birth or low birth weight for survivors of cancers other than Wilms tumor or for survivors who received treatments other than pelvic or abdominal irradiation is limited (10,15). Moreover, most of the previous studies addressing these pregnancy outcomes were small and included fewer than 100 childhood cancer survivors (8-10,13,15). To better evaluate the potential risk of preterm birth and diminished fetal growth among the offspring of female childhood cancer survivors and to examine this risk in relation to different cancer therapies (using quantified treatment exposures), we studied the pregnancies of female members of the ongoing Childhood Cancer Survivor Study (CCSS) (16). This study includes a large number of childhood cancer survivors who were treated for a wide array of cancers and who underwent a wide range of treatments.
- Published
- 2006
43. Dose Reconstruction for Therapeutic and Diagnostic Radiation Exposures: Use in Epidemiological Studies
- Author
-
Marilyn Stovall, Elaine Ron, Susan A. Smith, Ruth A. Kleinerman, Rita E. Weathers, Lois B. Travis, and Catherine E. Kasper
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Brachytherapy ,Biophysics ,Radiation Dosage ,Models, Biological ,Risk Assessment ,Imaging phantom ,Radiation Monitoring ,Risk Factors ,Dose estimation ,Epidemiology ,medicine ,Relative biological effectiveness ,Humans ,Computer Simulation ,Tissue Distribution ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Tissue distribution ,Radioisotopes ,Radiation ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Radiotherapy Dosage ,Environmental Exposure ,Radiation therapy ,Absorbed dose ,Body Burden ,Epidemiologic Methods ,business ,Relative Biological Effectiveness - Abstract
This paper describes methods developed specifically for reconstructing individual organ- and tissue-absorbed dose of radiation from past exposures from medical treatments and procedures for use in epidemiological studies. These methods have evolved over the past three decades and have been applied to a variety of medical exposures including external-beam radiation therapy and brachytherapy for malignant and benign diseases as well as diagnostic examinations. The methods used for estimating absorbed dose to organs in and outside the defined treatment volume generally require archival data collection, abstraction and review, and phantom measurements to simulate past exposure conditions. Three techniques are used to estimate doses from radiation therapy: (1) calculation in three-dimensional mathematical computer models using an extensive database of out-of-beam doses measured in tissue-equivalent materials, (2) measurement in anthropomorphic phantoms constructed of tissue-equivalent material, and (3) calculation using a three-dimensional treatment-planning computer. For diagnostic exposures, doses are estimated from published data and software based on Monte Carlo techniques. We describe and compare these methods of dose estimation and discuss uncertainties in estimated organ doses and potential for future improvement. Seven epidemiological studies are discussed to illustrate the methods.
- Published
- 2006
44. Risk of subsequent breast cancer after radiotherapy according to hormone-receptor status: A nested case-control study in the Childhood Cancer Survivor Study (CCSS)
- Author
-
Rochelle E. Curtis, Todd M. Gibson, Susan A. Smith, Amy Berrington de Gonzalez, Leslie L. Robison, Lene H.S. Veiga, Lindsay M. Morton, Gregory T. Armstrong, Chaya S. Moskowitz, Kevin C. Oeffinger, John Whitton, Peter D. Inskip, Wendy M. Leisenring, Lucie M. Turcotte, Tara O. Henderson, Rita E. Weathers, Joseph P. Neglia, Diana R. Withrow, and Rebecca M. Howell
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Childhood cancer ,Absolute risk reduction ,Childhood Cancer Survivor Study ,medicine.disease ,Radiation therapy ,Breast cancer ,Hormone receptor ,Internal medicine ,Nested case-control study ,medicine ,business - Abstract
10520 Background: Survivors of childhood cancer have a high absolute risk of subsequent breast cancer after chest-directed radiotherapy; however, it is not known if this risk differs by hormone-receptor status and radiation to the ovaries. Methods: We conducted a nested case-control study within the CCSS of 282 five-year survivors of childhood cancer with subsequent breast cancer and 1202 matched controls. Radiation dose to the location of the breast tumor (or corresponding location for controls) and mean dose to the ovaries were estimated from treatment records for each patient. Risk of radiation-related breast cancer was measured with the Excess Odds Ratio per Gray (EOR/Gy) and corresponding 95% confidence interval (CI), derived from conditional logistic regression. Results: The median age at subsequent breast cancer diagnosis was 39 years (range 21-58). Although 87% of cases and 70% of controls received radiotherapy, breast doses were higher in cases than controls (61% vs 24% breast dose > 10Gy), whereas ovarian doses were lower (7% vs 13% ovary dose > 5Gy). In the subset of cases (n = 159) with currently available estrogen receptor (ER) status (76% cases ER+, 24% cases ER-), there was a linear dose-response relation with radiation dose to the breast that was similar for ER+ (EOR/Gy = 0.51; 95%CI: 0.19-1.34) and ER- breast tumors (EOR/Gy = 0.41; 95%CI: 0.05-2.88). If the patient received an ovarian dose > 5Gy, this dose-response was significantly reduced for ER+ tumors but not for ER- tumors. Conclusions: Preliminary analyses demonstrate that radiation exposure to the breast to treat childhood cancer results in an increased risk of both ER+ and ER- breast cancers. The novel finding that only the risk of ER+ breast cancer is lowered if the ovaries are also exposed is consistent with known differences by hormone receptor status in the biological mechanisms of breast carcinogenesis.
- Published
- 2017
45. Increased stomach cancer risk following radiotherapy for testicular cancer
- Author
-
Charles F. Lynch, Rita E. Weathers, Preetha Rajaraman, Leila Vaalavirta, J. F. Fraumeni, S. A. Smith, Eric J. Holowaty, Lindsay M. Morton, Frøydis Langmark, Berthe M.P. Aleman, Eero Pukkala, Hans H. Storm, Sophie D. Fosså, Rochelle E. Curtis, Lois B. Travis, Graça M. Dores, Magnus Kaijser, Heikki Joensuu, Marilyn Stovall, Michael Andersson, A.W. van den Belt-Dusebout, Ruth A. Kleinerman, F.E. van Leeuwen, Per Hall, Ethel S. Gilbert, Michael Hauptmann, and Tom Børge Johannesen
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,Adolescent ,medicine.medical_treatment ,chemotherapy ,Gastroenterology ,Cohort Studies ,Young Adult ,Testicular Neoplasms ,Stomach Neoplasms ,Internal medicine ,medicine ,Humans ,Cumulative incidence ,Survivors ,Stomach cancer ,Testicular cancer ,radiotherapy ,Aged ,stomach cancer ,business.industry ,Stomach ,Incidence (epidemiology) ,Incidence ,Case-control study ,Dose-Response Relationship, Radiation ,Radiotherapy Dosage ,Odds ratio ,Middle Aged ,medicine.disease ,3. Good health ,Surgery ,testicular cancer ,Radiation therapy ,medicine.anatomical_structure ,Oncology ,Case-Control Studies ,Clinical Study ,Female ,business - Abstract
Background: Abdominal radiotherapy for testicular cancer (TC) increases risk for second stomach cancer, although data on the radiation dose–response relationship are sparse. Methods: In a cohort of 22 269 5-year TC survivors diagnosed during 1959–1987, doses to stomach subsites were estimated for 92 patients who developed stomach cancer and 180 matched controls. Chemotherapy details were recorded. Odds ratios (ORs) were estimated using logistic regression. Results: Cumulative incidence of second primary stomach cancer was 1.45% at 30 years after TC diagnosis. The TC survivors who received radiotherapy (87 (95%) cases, 151 (84%) controls) had a 5.9-fold (95% confidence interval (CI) 1.7–20.7) increased risk of stomach cancer. Risk increased with increasing stomach dose (P-trend
- Published
- 2014
46. SYMPTOM MANAGEMENT/QUALITY OF LIFE
- Author
-
Jeffrey S. Wefel, C. Marc Leyer, Deborah Schrag, Indranil Sen-Gupta, Olivier Chinot, Elaine Shing, Elizabeth Vera-Bolanos, Charles A. Sklar, Michael Macken, Steven R Rapp, Michael D Chan, Silvia Focarelli, Lauren E. Abrey, Somali Burgess, Alvina Acquaye, Arimantas Tamašauskas, Mairi Mackinnon, Sabine Mueller, Matthew G. Ewend, Linda Douw, Antonella Benincasa, Nils D. Arvold, Ryo Nishikawa, Nikhil S. Padhye, Gabriele Röhn, Kelly Mills, Vinay K. Puduvalli, Helen McKenzie, Alan Carson, Michael D. Prados, Minhee Won, Thanh Tran, Eric T. Wong, Veronica Villani, Tobias Walbert, David Brachman, Doug Case, Andrea Pace, Gregory T. Armstrong, Francesca Dominici, Yoshihiro Muragaki, Stephan Schuele, John L. Villano, Warren P. Mason, Callie Choong, Mario E. Lacouture, Mollie D. Oudenhoven, Eli Diamond, Roy Rampling, Matthias Seibl-Leven, Michael Barton, Andrew Bottomley, Mitchell P. Rosen, Wilmy Cleijne, Jennifer E. Cahill, Adomas Bunevicius, Tito R. Mendoza, Eng-Siew Koh, David Tran, Jennifer Clarke, Giuseppe Stragliotto, Sarah Woltz, Petra Hoogendoorn, Aidan Burke, Lonni Schultz, Nicholas Butowski, Janette L. Vardy, Marianne Gröntoft, Ann M. Peiffer, Karen Robinson, Cory Zigler, William T Kearns, Wolfgang Wick, Mary Ellen Maher, Martin J.B. Taphoorn, H. Ian Robins, Irena Garic, Mary Elizabeth Davis, Cat Graham, Marilyn Stovall, Terri S. Armstrong, Christina Amidei, Vytenis Pranas Deltuva, Kristen Lawton, Jane Rabbitt, Mary Lovely, Hiroshi Iseki, Martin Klein, Magalie Hilton, Hinke F. van Thuijl, Jeffrey Raizer, Jan J. Heimans, Alan Shilds, Edward G. Shaw, Jeffrey Kennedy, Teresa Simpson, Mark R. Gilbert, Kylie M. Wright, Wendy Sherman, Masayuki Nitta, R. Jeffrey Lee, Kevin R. Krull, Takashi Maruyama, Marjolein de Groot, Alfredo Pompili, Manabu Tamura, Kathy Lupica, Florien W. Boele, Iyar Mazar, Roland Goldbrunner, Jessica Chan, Lin Lin, Fiona Taylor, Martin J B Taphoorn, Lisa M. DeAngelis, Diana Sullivan, Antonio P. DeRosa, Elizabeth Gerard, S. McNamara, Emily Porensky, Herbert B. Newton, Sarunas Tamasauskas, Frank Saran, William H. Hinson, Arliene Ravelo, Robert Cavaliere, Soko Ikuta, Leslie L. Robison, Paul D. Brown, Casey Farin, Minesh P. Mehta, Robertas Bunevičius, Simon Kerrigan, Kathy Mogensen, Kayla Stratton, Mary Fraser, Heather J. Fullerton, Grace Elzinga, Dianne Legge, Marco Timmer, Carmine Maria Carapella, Geoffrey Corner, Robert E. Goldsby, Meredith M. Wendland, Saori Okamoto, Terri Armstrong, Dario Benincasa, Jean Arzbaecher, Jaap C. Reijneveld, Robin Grant, Riane Hoffman, Stephanie L. Pugh, Yoshikazu Okada, Allison J. Applebaum, Ashley A. DeSilva, Timothy F. Cloughesy, Wendy M. Leisenring, Margaretta Page, L. Heimans, Lawrence Cher, Jing Wu, William Breitbart, Alasdair G Rooney, Rita E. Weathers, Roger Henriksson, Klaus Wittenstein, Michael Glantz, Wafa Trad, Elizabeth Hovey, Caroline Chung, Yun Wang, and Ian R. Crocker
- Subjects
Cancer Research ,medicine.medical_specialty ,Abstracts ,Quality of life (healthcare) ,Oncology ,business.industry ,Symptom management ,Medicine ,Neurology (clinical) ,business ,Intensive care medicine - Published
- 2013
47. Radiation dose and subsequent risk for stomach cancer in long-term survivors of cervical cancer
- Author
-
Ethel S. Gilbert, Berthe M.P. Aleman, Ruth A. Kleinerman, Heikki Joensuu, Rita E. Weathers, Hans H. Storm, Eero Pukkala, Susan A. Smith, Graça M. Dores, Leila Vaalavirta, Rochelle E. Curtis, Charles F. Lynch, Eric J. Holowaty, Marilyn Stovall, Lois B. Travis, Michael Andersson, Per Hall, Lindsay M. Morton, and Magnus Kaijser
- Subjects
Oncology ,Adult ,Risk ,Cancer Research ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,medicine.medical_treatment ,Population ,Brachytherapy ,Uterine Cervical Neoplasms ,Article ,Stomach Neoplasms ,Internal medicine ,Confidence Intervals ,Odds Ratio ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Registries ,Survivors ,education ,Stomach cancer ,Aged ,Cervical cancer ,Aged, 80 and over ,education.field_of_study ,Radiation ,business.industry ,Stomach ,Cancer ,Dose-Response Relationship, Radiation ,Radiotherapy Dosage ,Odds ratio ,Middle Aged ,medicine.disease ,Radiation therapy ,medicine.anatomical_structure ,Case-Control Studies ,Female ,business - Abstract
Purpose To assess the dose–response relationship for stomach cancer after radiation therapy for cervical cancer. Methods and Materials We conducted a nested, matched case–control study of 201 cases and 378 controls among 53,547 5-year survivors of cervical cancer diagnosed from 1943 to 1995, from 5 international, population-based cancer registries. We estimated individual radiation doses to the site of the stomach cancer for all cases and to corresponding sites for the matched controls (overall mean stomach tumor dose, 2.56 Gy, range 0.03-46.1 and after parallel opposed pelvic fields, 1.63 Gy, range 0.12-6.3). Results More than 90% of women received radiation therapy, mostly with external beam therapy in combination with brachytherapy. Stomach cancer risk was nonsignificantly increased (odds ratio 1.27-2.28) for women receiving between 0.5 and 4.9 Gy to the stomach cancer site and significantly increased at doses ≥5 Gy (odds ratio 4.20, 95% confidence interval 1.41-13.4, P trend =.047) compared with nonirradiated women. A highly significant radiation dose–response relationship was evident when analyses were restricted to the 131 cases (251 controls) whose stomach cancer was located in the middle and lower portions of the stomach ( P trend =.003), whereas there was no indication of increasing risk with increasing dose for 30 cases (57 controls) whose cancer was located in the upper stomach ( P trend =.23). Conclusions Our findings show for the first time a significant linear dose–response relationship for risk of stomach cancer in long-term survivors of cervical cancer.
- Published
- 2012
48. Abstract 2691: Genome-wide association study identifies two susceptibility loci that modify radiation-related risk for breast cancer after childhood cancer: A report from the Childhood Cancer Survivor Study and St. Jude Lifetime Cohort
- Author
-
Zhaoming Wang, Wendy M. Leisenring, Peter D. Inskip, Shenchao Li, Meredith Yeager, Kevin C. Oeffinger, Joseph P. Neglia, Gretchen A. Radloff, Gregory T. Armstrong, Aurelie Vogt, Wei Liu, Carmen L. Wilson, Preetha Rajaraman, Ting-Huei Chen, Chaya S. Moskowitz, Belynda Hicks, Leslie L. Robison, Matthew Lear, Marilyn Stovall, Sue Hammond, Mitchell J. Machiela, Jeannette R. Wong, Lindsay M. Morton, Melissa M. Hudson, Diana M. Merino, Louise C. Strong, John Whitton, William Wheeler, Margaret A. Tucker, Kumar Srivastava, Laura Bowen, Lucie M. Turcotte, Susan A. Smith, Jeremy A. Miller, Stephen J. Chanock, Rita E. Weathers, Todd M. Gibson, Eric Karlins, Guolian Kang, Yutaka Yasui, Rebecca M. Howell, Joseph F. Fraumeni, Joshua N. Sampson, Tara O. Henderson, Laurie Burdette, Casey L. Dagnall, Smita Bhatia, Amy Berrington de Gonzalez, Stella M. Davies, and Geoffrey Neale
- Subjects
Oncology ,Cancer Research ,education.field_of_study ,medicine.medical_specialty ,Proportional hazards model ,business.industry ,medicine.medical_treatment ,Population ,Genome-wide association study ,Childhood Cancer Survivor Study ,medicine.disease ,Radiation therapy ,Breast cancer ,Internal medicine ,Genetic model ,Cohort ,medicine ,education ,business - Abstract
Background: Childhood cancer survivors treated with chest radiotherapy have substantially elevated risk for developing breast cancer. Although numerous breast cancer susceptibility variants have been established, genetic predisposition for breast cancer after childhood cancer remains poorly understood. Methods: We conducted the first genome-wide association study of subsequent breast cancer in female childhood cancer survivors within two large-scale cohorts with detailed treatment data and systematic, long-term follow-up: the Childhood Cancer Survivor Study [CCSS; 178 breast cancer cases, 2200 controls (survivors without subsequent neoplasm) of European descent] and the St. Jude Lifetime Cohort (SJLIFE; 29 cases, 574 controls). Genotyping on the Illumina HumanOmni5MExome (CCSS) or Affymetrix 6.0 (SJLIFE) array and imputation based on the 1000 Genomes Project yielded >16 million high quality genotyped or imputed variants available in both studies. Assuming an additive genetic model, we used multivariate Cox regression to quantify the effect of each variant in the overall population and stratified by receipt of ≥10 Gray (Gy) or Results: We identified two loci associated with breast cancer risk among children who received ≥10 Gy radiation to the chest (131 cases, 493 controls): one at 1q41 [rs4342822, risk allele frequency (RAF) = 0.46 in controls, pooled per allele hazard ratio (HR) = 1.94, 95% confidence interval (CI) = 1.50-2.51, Pexact = 1.20×10−8] and another at 11q23 (rs74949440, RAF = 0.02 in controls, HR = 3.71, 95%CI = 2.18-6.32, Pexact = 2.00×10−9). Neither locus was associated with breast cancer risk among children who received 10% of breast cancers in The Cancer Genome Atlas data. The variant rs74949440 is intronic to TAGLN, whose expression levels have been associated with breast cancer prognosis and altered cell death resistance following irradiation in human carcinoma cell lines. Conclusion: These findings represent the first evidence outside of identified high-risk cancer susceptibility genes that certain individuals are genetically predisposed to developing breast cancer after radiotherapy and suggest that radiation exposure may interact with germline genetics to modify breast cancer risk. Citation Format: Lindsay M. Morton, Joshua N. Sampson, Gregory T. Armstrong, Ting-Huei Chen, Melissa Hudson, Eric Karlins, Casey L. Dagnall, Shenchao Li, Carmen L. Wilson, Kumar Srivastava, Wei Liu, Guolian Kang, Kevin Oeffinger, Tara O. Henderson, Chaya S. Moskowitz, Todd M. Gibson, Diana M. Merino, Jeannette R. Wong, Sue Hammond, Joseph P. Neglia, Lucie M. Turcotte, Jeremy Miller, Laura Bowen, William A. Wheeler, Wendy M. Leisenring, John A. Whitton, Laurie Burdette, Belynda D. Hicks, Mitchell J. Machiela, Aurelie Vogt, Zhaoming Wang, Meredith Yeager, Geoffrey Neale, Matthew Lear, Louise C. Strong, Yutaka Yasui, Marilyn Stovall, Rita E. Weathers, Susan A. Smith, Rebecca Howell, Stella M. Davies, Gretchen A. Radloff, Amy Berrington de González, Peter D. Inskip, Preetha Rajaraman, Joseph F. Fraumeni, Smita Bhatia, Stephen J. Chanock, Margaret A. Tucker, Leslie L. Robison. Genome-wide association study identifies two susceptibility loci that modify radiation-related risk for breast cancer after childhood cancer: A report from the Childhood Cancer Survivor Study and St. Jude Lifetime Cohort. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2691.
- Published
- 2016
49. Genome-wide association study of meningioma as a subsequent neoplasm: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort (SJLIFE)
- Author
-
Margaret A. Tucker, Lindsay M. Morton, Stephen J. Chanock, Rita E. Weathers, Joseph Philip Neglia, Wei Liu, Yutaka Yasui, Gregory T. Armstrong, Melissa M. Hudson, Ting-Huei Chen, Deo Kumar Srivastava, Susan A. Smith, Smita Bhatia, Leslie L. Robison, Carmen L. Wilson, Casey L. Dagnall, Joshua N. Sampson, Guolian Kang, Eric Karlins, and Todd M. Gibson
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Childhood cancer ,Genome-wide association study ,Childhood Cancer Survivor Study ,medicine.disease ,Meningioma ,Increased risk ,Cranial Irradiation ,Internal medicine ,Cohort ,medicine ,Neoplasm ,business - Abstract
10510Background: Survivors of childhood cancer treated with cranial irradiation have a dose-dependent increased risk of meningiomas, which may cause significant morbidity. However, surveillance gui...
- Published
- 2016
50. Cancer Mortality Following Radiotherapy for Benign Gynecologic Disorders
- Author
-
Ritsu Sakata, Marilyn Stovall, Diane Cookfair, John D. Boice, Susan A. Smith, Kiyohiko Mabuchi, Ruth A. Kleinerman, Peter D. Inskip, Rita E. Weathers, and Jean Wactawski-Wende
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Genital Neoplasms, Female ,medicine.medical_treatment ,Population ,Biophysics ,Rectum ,GYNECOLOGIC DISORDERS ,Article ,Medical physicist ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,education ,Aged ,Cancer mortality ,Aged, 80 and over ,education.field_of_study ,Radiation ,business.industry ,Middle Aged ,Surgery ,Radiation therapy ,Standardized mortality ratio ,medicine.anatomical_structure ,Female ,Bone marrow ,business - Abstract
The purpose of this study is to quantify cancer mortality in relationship to organ-specific radiation dose among women irradiated for benign gynecologic disorders. Included in this study are 12,955 women treated for benign gynecologic disorders at hospitals in the Northeastern U.S. between 1925 and 1965; 9,770 women treated by radiation and 3,186 women treated by other methods. The average age at treatment was 45.9 years (range, 13–88 years), and the average follow-up period was 30.1 years (maximum, 69.9 years). Radiation doses to organs and active bone marrow were reconstructed by medical physicists using original radiotherapy records. The highest doses were received by the uterine cervix (median, 120 Gy) and uterine corpus (median, 34 Gy), followed by the bladder, rectum and colon (median, 1.7–7.2 Gy), with other abdominal organs receiving median doses ≤1 Gy and organs in the chest and head receiving doses
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.